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INTRODUCTION 
 
 Gods interest in the human race is nowhere better evinced than in 
obstetrics – Martin H. Fischer. 
 Child birth is one of the most marvelous and memorable segment in a 
woman’s life. The art of vaginal birth is a unique experience and calls for a 
celebration. Although the incidence of caesarean section is increasing 
throughout the world, the art of vaginal birth has not lost its charm. Birth is a 
life changing event. The care given to woman during labour has the potential to 
affect her both physically and emotionally in the short and long term.  
Though labour is a physiological process, it is often associated with 
morbidity and mortality. The most common cause being blood loss. Life 
threatening obstetric hemorrhage occurs in approximately 1 per 1000 deliveries. 
The most recent Practice Bulletin from the American College of  Obstetrics and 
Gynaecology places the estimate at 1,40,000 maternal deaths per year or 1 
woman every 4 minutes.  There are a number of drugs available for the 
management of PPH. The recent ones being the anti fibrinolytics and 
recombinant factor VIIa. 
Postpartum haemorrhage (PPH) remains a leading cause of maternal 
mortality, especially in developing countries (Ronsmons 2006). In confidential 
enquiries into maternal deaths in South Africa (2005 to 2007) (Confidential 
enquiries 2006), 383 maternal deaths due to PPH were reported and the 
majority of these were considered to be preventable. Of these deaths, 67 
  
2 
(17.5%) were caused by uterine atony, where uterotonics were required to 
control the bleeding. Other cases of maternal death from PPH were due to 
uterine rupture (37 in women with previous caesarean sections and 43 in 
women without previous caesarean sections), retained placenta (88), inverted 
uterus (seven), and other genital tract trauma including caesarean section (141). 
The great majority were thus not due to uterine atony, and attempts to address 
the problem need to go beyond the use of uterotonic drugs. Because of the 
difficulty of randomised trials in women presenting with PPH, the use of 
tranexamic acid for preventing PPH in high-risk women could be regarded as a 
proxy for assessing its use for treating PPH. In particular, high-risk factors 
which may not be responsive to uterotonics, such as placenta praevia and 
lacerations from instrumental delivery, may respond to tranexamic acid. If 
tranexamic acid is found to be effective in the prevention of PPH in such high-
risk women, its use could be extrapolated to the treatment of PPH (as has been 
the case for most treatments for PPH, such as oxytocin and ergometrine). 
The changes in the fibrinolytic components during and immediately 
after placental delivery are consistent with fibrinolysis occurring as a response 
to local fibrin deposition. The plasma fibrinogen level decreases during the 3rd 
stage of labour and after placental delivery, and the level of fibrin/ fibrinogen 
degradation products in the serum increases 1 hour after child birth and remains 
raised in the early puerperium. 
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Hence antifibrinolytics will be effective in reducing blood loss by 
interacting with the fibrinolytic mechanism. 
This study observes the blood loss reduced by Tranexamic Acid, an 
antifibrinolytic agent during 3rd stage. 
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AIM OF THE STUDY 
 
 
 
1. To evaluate the efficacy of parenteral Tranexamic Acid in reducing 
blood loss during normal labour. 
2. To compare it with the amount of blood loss in patients who did not 
receive Tranexamic Acid in the 3rd stage. 
  
 
 
 
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
 
Post partum hemorrhage is the leading cause of maternal mortality. All 
woman who carry a pregnancy beyond 20 weeks gestation are at risk of PPH 
and its sequelae. In the developing world, several countries have maternal 
mortality rates in excess of 1000 women per 100,000 live births and WHO 
statistics suggest that 25% of maternal deaths are due to PPH, accounting for 
more than 100,000 maternal deaths per year. 
The leading causes of pregnancy related death are hemorrhage, 
embolism and hypertensive disorders of pregnancy – Berg CJ et al 1996. 
Prendiville et al. in Bristol Third Stage Trial found an incidence of 
postpartum bleeding of 5.9% in actively managed group and 17.9% in 
physiologically managed group. They concluded that intervention in third stage 
of labour reduces the risk of PPH by 30 – 40%. 
MrCormick et al. published a systematic review of studies that 
assessed the efficacy of intervention in 3rd stage – concluded that intervention 
reduced the incidence of PPH, decreased the need for blood transfusion and 
decreased the need for additional uterotonic drugs. 
 Malcolm Potts 2006 – Darwinian evolution is not about what is nice, 
safe or aesthetic, but about what works. Human beings are burdened with a 
highly invasive trophoblast and at delivery, the human placenta leaves a huge, 
20cm diameter wound on the inside of the uterus. The potential of 
catastrophically heavy bleeding can be avoided only by powerful uterine 
contractions and a good coagulation mechanism. 
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Idara Udofia et al. 2008 – Any intervention aimed at preventing PPH 
will reduce maternal mortality by more than one quarter. 
 
Blood loss during normal labour 
Normal pregnancy is accompanied by changes in the haemostatic 
mechanisms, particularly increase in the levels of factor VII, VIII, X and 
fibrinogen and a pronounced decrease in fibrinolytic activity. Parturition 
presents a serious challenge to the vascular compartment, but it has been 
generally held (Taylor, 1966; Donald, 1969) that contraction of the 
myometrium “the living ligatures” of the uterus - is the mechanism which, 
mainly controls blood loss at delivery. In the other situations where there is 
injury to the vascular tree an efficient blood coagulation system plays a vital 
part in achieving effective haemostasis and preserving the blood volume. 
The coagulation and fibrinolytic mechanisms may be in a state of 
dynamic equilibrium which keeps the vascular compartment intact and patent, 
the coagulation system laying down fibrin to seal any gaps in the vascular 
endothelium and the fibrinolytic mechanism removing the deposits of fibrin 
after they have served their haemostatic function. Fibrinolytic activity is known 
to be decreased in the late pregnancy and labour and to return to normal in 
early puerperium. 
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Physiological adaptations in pregnancy 
Antepartum adaptations for physiological blood loss at delivery include 
a 42% increase in plasma volume and a 24% increase in red blood cell volume 
by the third trimester. Progressively complicated deliveries are accompanied by 
greater degrees of blood loss. 
Vaginal delivery – 500ml 
Caesarean section – 1000ml 
Caesarean hysterectomy – 1500ml 
Emergency hysterectomy – 3500ml 
However, these thresholds do not take into account the pre-existing health 
status and blood loss of as little as 200ml can be life threatening for a woman 
with severe anemia or cardiac disease (Kongnyuy et al., 2009). 
 
GREENTOP GUIDELINES (RCOG 2007) – defines PPH as 
• 1 blood volume loss / 24 hrs 
• 150 ml / minute blood loss 
• 50% blood volume loss / 3 hrs 
Some of the factors leading to increased blood loss in the third stage 
labour are as follows: 
• Mean vaginal blood loss is higher in multiparae than in primiparae 
• In primiparae, forceps delivery is associated with greater blood loss than 
spontaneous delivery; this is related to the episiotomies and other 
injuries to the genital tract. 
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• Patients with an episiotomy and a laceration lose significantly more 
blood than those without such insult. Episiotomies contribute to 154 ml 
to the average blood loss. 
 
Incidence of PPH 
2% to 11% - when blood loss is estimated visually (Brent et al., 1967) 
20% - when blood loss is estimated by quantitative methods (Newton et al., 
1961) 
 
Types of PPH 
 1° PPH / early PPH – which occurs within 24 hrs of delivery  
 2° PPH / late PPH – which occurs 24 hrs to 6 weeks after delivery 
Most cases of PPH almost 99% are due to 1° PPH  
 
Pathophysiology  
At term the uterus and placenta receive 500 – 800 ml of blood per 
minute through their low resistance network of vessels. This high flow 
predisposes a gravid uterus to significant bleeding if not well physiologically or 
medically controlled.  By the third trimester, maternal blood volume increases 
by 40% - 50%, which increases the body's tolerance of blood loss during 
delivery. Following delivery of the fetus, the gravid uterus is able to contract 
down significantly given the reduction in volume. This allows the placenta to 
separate from the uterine interface, exposing maternal blood vessels that 
interface with the placental surface. After separation and delivery of the 
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placenta, the uterus initiates a process of contraction and retraction, shortening 
its fiber and kinking the supplying blood vessels, like physiologic sutures or 
"living ligatures." 
If the uterus fails to contract, or the placenta fails to separate or deliver, 
then significant hemorrhage may ensue. Uterine atony, or diminished 
myometrial contractility, accounts for 80% of postpartum hemorrhage. The 
other major causes include abnormal placental attachment or retained placental 
tissue, laceration of tissues or blood vessels in the pelvis and genital tract, and 
maternal coagulopathies. An additional, though uncommon, cause is inversion 
of the uterus during placental delivery. 
Potential causes for increased blood loss during labour: 
1. Tone loss  
2. Trauma 
3. Tissue retention 
4. Thrombotic defect 
Of these, tone loss is the commonest and thrombotic defect is the most 
difficult to treat. 
 
1. TONE LOSS : 80%, the following are the predisposing factors  
• Multiparity 
• Uterine overdistension – multiple pregnancy, hydramnios, macrosomia 
• Prolonged labour 
• Precipitate labour  
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• Anemia 
• Chorioamnionitis 
• Uterine abnormalities or fibroids 
• Previous H/O PPH  
• Induced labour  
• Inadvertent use of oxytocics 
• Drugs – halogenated anaesthetics, MgSO4, nifidepine, beta agonists, 
diazoxide 
• Placenta – accreta, praevia, abruption 
2. TRAUMA : 20% 
Lacerations and haematomas resulting from birth trauma can cause 
significant blood loss that can be lessened by haemostasis and timely repair. 
Factors causing increased blood loss are: 
• Obstructed labour 
• Big baby 
• Pfannensteil incision 
• Transverse lie 
• Classical caesarean section 
• Poor obstetrician’s skill 
3. TISSUE RETENSION : 10% 
Placenta, accreta, increta, percreta, missed cotyledons and succenturiate 
placental lobe. 
  
11 
Risk factors 
• Advanced maternal age 
• High parity 
• Previous invasive placenta 
• Previous caesarean section  
• Placenta praevia 
• Previous H/O manual removal of placenta  
4. THROMBOTIC DEFECT: 5% 
• Coagulopathies – ITP, TTP, VWD, hemophilia 
• Acquired – HELLP, abruption, IUD, DIC, septicemia 
PPH is a potentially life threatening complication of both vaginal and 
caesarean delivery. Associated morbidity is related to the direct consequences 
of blood loss as well as the potential complications of haemostatic and 
resuscitative interventions.  
Consequence of uncontrolled haemorrhage include 
• Hypovolemic shock and associated organ failure including renal failure, 
stroke, myocardial infarction 
• Postpartum hypopituitarism (Sheehan syndrome): Acute blood loss and / or 
hypovolemic shock during and after childbirth can lead to hypoperfusion of 
the pituitary and subsequent necrosis. Although often asymptomatic, it may 
present with an inability to breastfeed, fatigue, hypogonadism, amenorrhea, 
and hypotension. 
• Death secondary to hypovolemic shock 
  
12 
Consequences of fluid resuscitation 
• Fluid overload can lead to extremity edema and pulmonary edema. The 
latter is less common in young healthy women, but it should be suspected in 
the setting of large fluid and blood product resuscitation. 
• Dilutional coagulopathy occurs when crystalloids and/or serum-poor blood 
products are given in large volume. 
 
Risks from exposure to blood products 
• Allergic or febrile reactions have an incidence of about 1 case per 333 
population. 
• Anaphylactic reactions occur in 1 in 20,000 to 1 in 47,000 blood 
products transfused. 
• Transfusion-related acute lung injury (TRALI) occurs in 1 out of every 
5,000 transfusions, but more often with high plasma containing products 
like fresh frozen plasma (FFP) and platelets. It often starts within 1-2 
hours of the transfusion, but it can happen anytime up to 6 hours after a 
transfusion. The symptom complex includes severe bilateral pulmonary 
edema, severe hypoxemia, tachycardia, cyanosis, hypotension, and 
fever. 
• Acute immune hemolytic reaction, though rare, is the most serious type 
of transfusion reaction. Symptoms are associated with red blood cell 
hemolysis. Patients may have fevers, chills, chest and lower back pain, 
nausea, renal failure, and death if the transfusion is not stopped. 
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• Delayed hemolytic reaction: This type of reaction happens when the 
body slowly attacks antigens (other than ABO antigens) on the 
transfused blood cells. Symptoms occur days to weeks after a 
transfusion. Affected patients are either asymptomatic or have mild 
symptoms, which may include jaundice, low-grade fever, and a low 
hemoglobin or hematocrit 
 
Infection 
Hepatitis is the most common disease transmitted by blood transfusions.  
According to the American Red Cross, about 1 blood transfusion in 
205,000 transmits a hepatitis B infection, and 1 blood transfusion in about 2 
million transmits hepatitis C.  
Other rare but potential infections include HIV (risk of 1 in 2.5 million), 
Lyme disease, babesiosis, and malaria. Donors are screened for potential 
exposure so transmission is very rare. Rarely, blood may be contaminated with 
tiny amounts of skin bacteria during donation. Platelets are the most likely 
blood product to be affected by contamination from skin flora. 
• Metabolic reactions: With large volume and rapid transfusions, patients 
are at risk of encountering 3 metabolic reactions: hypothermia, 
hyperkalemia, and citrate toxicity. 
• Hypothermia results from the transfusion of unwarmed crystalloid or 
colloid that drops the body temperature. Hypothermia inhibits 
coagulation and can worsen postpartum hemorrhage. Citrate is a blood 
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product additive that binds serum calcium and can cause hypocalcemia 
with large-volume transfusions. Hemolysis occurs with red blood cell 
storage releasing increasing amounts of intracellular potassium with 
time. Transfusions of older red blood cells increase the risk of 
hyperkalemia. 
Risks associated with surgical intervention 
• Intubation and anesthesia complications: Pregnant women have an 
increased risk for aspiration, failed intubation, and death from failed 
ventilation when compared with nonpregnant patients. Respiratory 
injury or infection, myocardial infarction, myocardial arrhythmia, 
stroke, or allergic reactions to anesthetic medications may also rarely 
occur. 
Bleeding: Continued bleeding from the genital tract or a bleeding 
complication from the surgery may occur. 
Infection: Sepsis, wound infection, or pneumonia is possible. 
• Deep venous thrombosis and/or pulmonary embolism: Risk is increased 
due to postpartum and postoperative associated hypercoagulability as 
well as from relative immobility in the operative and postoperative 
period. 
If the bleeding cannot be controlled conservatively (removal of products 
of conception, suturing disrupted tissues, application of pressure) then 
surgical intervention may be necessary. In severe cases, the following 
may occur: 
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• Hysterectomy 
• Asherman syndrome, which is secondary (non-hormone mediated) 
amenorrhea due to uterine scarring that develops after infection and/or 
curettage performed to remove placental fragments 
 
BLOOD LOSS ASSESSMENT  
In order to assess the efficiency of the drug, the blood loss assessment 
has to be standardized. 
 
Clinical methods 
1. By subjective characters 
2. Visual estimation 
1. Estimation by subjective characters 
• Shock index 
SI = HEART RATE / SYSTOLIC BP 
NORMAL = 0.5 – 0.7, with significant hemorrhage, it increases to 0.9 – 1.1 
 
• Rule of 30 
1. If systolic BP falls by 30 mmHg 
2. Heart rate rises by 30 bpm 
3. Respiratory rate rises by 30 breaths per minute 
4. Hb or Hct drops by 30% 
5. Urine output < 30 ml per hour 
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Patient is said to have lost atleast 30% of blood volume if all the above 
exists. 
 
• Measurement of CVP 
Normal : 8 – 14 cm of water. If CVP is low 0-6 cm of water, it means 
the blood volume is low in relation to cardiac capacity. If CVP is high > 15 cm 
of water, it means the blood volume is high in relation to cardiac capacity. 
 
• Classification of haemorrhage 
PARAMETER CLASS I CLASS II CLASS III CLASS IV 
Blood loss (ml) < 750 750 – 1500 1500 - 2000 > 2000 
Blood loss (%) < 15 15 – 30 30 – 40 > 40 
Pulse rate/min < 100 > 100 > 120 > 140 
Blood pressure N ↓ ↓ ↓ 
Respiratory rate/min 14 – 20 20 – 30 30 – 40 > 40 
Urine output (ml/hr) > 30 20 – 30 5 – 15 Negligible 
CNS symptoms Normal Anxious Confused Lethargic 
 
 
2. Visual estimation 
This is the most frequently practiced method. The incidence of PPH is 
underestimated in the visual estimation by 89% - Brant & Duthie et al. 
Budny et al. reported a strong positive association between calculated 
blood loss and blood loss estimated by junior and senior surgeons. It is 
inconsistent.  
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Dr. P. Bore et al. 2006 
• 10 × 10 cm swab = 60 ml 
• 30 × 30 cm swab = 140 ml 
• 45 × 45 cm swab = 350 ml 
• 1 kg soaked swabs = 1000 ml 
• 50 cm diameter floor spill = 500 ml 
• 75 cm diameter floor spill = 1000 ml 
• 100 cm diameter floor spill = 1500 ml 
Gravimetric methods 
• Patient weighing method 
• Swab weighing method 
By measuring the weight of the patient or swabs prior to and after delivery. 
- Patient weighing method: allowance must be made for drain, 
dressings, infection, tissue removal and insensible water loss. 
- Swab weighing method: 1 gm of weight gain = 1 ml of blood loss  
(Bonica and Lyter et al. in 1951, Harding 1984). Swabs must be 
weighed immediately to avoid the loss due to evaporation. Inter observer 
variation or inconsistency can be avoided in this method. 
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Calibrated obstetric drape 
This comes in sterile packing and fold out to a 1 × 1 metre sterile area 
for a woman to give birth. At the bottom of the sterile area is a pouch that holds 
more than 2500 ml of fluid, allowing for accurate measurement of postpartum 
blood loss.  The pouch itself also includes a flexible plastic filter to 'catch' 
material that is not liquid. The pouch includes a wire around its 'mouth' that 
keeps the pouch open. 
 
 
Colorimetric method: (Roe et al., 1962, Thornton et al., 1963,  Rustad et 
al., 1963) 
The washing of the blood contaminated swabs is carried out in a known 
volume of tap water to which has been added sufficient amount of ammonium 
hydroxide to give a 1 in 1000 dilution as a defoaming agent. The blood 
collected in the suction container has to be added to the water and the 
concentration of the resultant solution has to be determined. 
Blood loss in ml = Hb% of  washing fluid × volume of  washing fluid
Hb% of  patient's blood × dilution factor of  patient's Hb
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Measurement of blood in the suction apparatus 
Blood in the suction container can be measured. Inaccuracy in this 
method can be reduced by having measuring cylinder in the suction line and 
adding defoaming agent to the container. 
 
Electrolyte conductivity method : (Leveen and Rubricius et al., 1958) 
Using automated blood loss meter based on electrolyte conductivity. 
 
Radioactivity method : (Murray and Dott’s et al., 1960) 
Intravenous injection of small but known amount of radio isotope should 
be followed by measuring the radioactivity of blood on swabs collected during 
delivery. 
 
Blood volume measurements 
- Dye method: using evans blue dye which must neither be catabolised 
nor rapidly lost from the circulation 
- Radio isotopes like I131 labelled albumin or Cr51 labelled RBC can be 
used before delivery and measuring the post delivery radio activity by 
Geiger – Muller counter. (Mollison ans Veall et al., 1955). 
Among the above mentioned methods swab weighing method and blood 
collected in the calibrated obstetric drape measurement are practically possible 
and feasible methods that were used in our study. 
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REDUCING BLOOD LOSS 
Done by the following measures 
• Antenatal care 
• First and Second stage measures 
• Third stage measures 
• Postpartum measures 
 
Antenatal care 
1. Develop a birth preparedness plan : women should plan to give birth 
with a skilled attendant who can provide interventions to prevent, 
identify and manage PPH. 
2. Routinely screen to prevent and treat anemia during preconceptional, 
antenatal, postpartum visits. 
3. Blood grouping and Rh typing to be done. 
4. Correction of coagulation abnormality in case of abruption, IUD, 
HELLP syndrome. 
During first and second stage 
1. A woman in established labour should receive supportive one to one 
care 
2. Limit induction and augmentation use for medical and obstetric reasons 
3. Do not encourage pushing before cervix is fully dilated 
4. Do not apply fundal pressure to assist the birth of the baby 
5. Perineal massage should not be performed by healthcare professionals 
  
21 
6. Encourage the woman to keep her bladder empty 
7. Do not perform routine episiotomy 
8. Either “hands on” or the “hands poised’ techniques can be used to 
facilitate spontaneous birth 
 
During third stage : provide Active Management Of Third Stage Of Labour 
Postpartum measures 
It has been suggested that drainage of blood from the placenta would 
reduce its bulkiness, allowing the uterus to contract and retract and thus aiding 
delivery (Roger et al., 1988). 
Placental cord drainage may be used in conjunction with other 
interventions such as routine administration of oxytocics, controlled cord 
traction or maternal effort (Hinchongbrooks RCT Lancet, 1998). 
Placental cord drainage with or without prophylactic oxytocics is 
effective in reducing the blood loss in third stage thus preventing PPH (Keirse, 
1998). 
Timing at cord clamping is also an important factor in the management 
of third stage of labour, influences the duration of third stage (McDonald, 
2003). 
These are evidences to indicate that there are benefits in active 
management of third stage of labour, but it may be associated with increased 
nausea, vomiting and raised blood pressure (Prendiville et al., 2003). 
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The overall meta – analysis results of Cochrane database systematic 
reviews 2004, showed that there was a tendency for the active management 
group to have higher incidence of these complications. But this did not reach 
statistical significance. There was no statistically significant difference in 
neonatal outcome or breast feeding rates and no difference in long term 
maternal outcome. 
 
TREATMENT 
Most maternal deaths in PPH are due to the 3 delays: 
1. Delay in recognition of complications 
2. Delay in institution of definitive management 
3. Delay in referral / accessing transportation 
 
MANAGEMENT 
General 
Specific 
i) medical  
ii) surgical 
General Management 
- Assessment of general condition of the patient, the amount of blood loss 
and degree of hypoxemia 
- Vital parameters should be recorded 
- 100 % oxygen by face mask should be given 
- 2 large bore iv cannula should be secured 
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- Blood should be sent for cross matching, CBC, RFT 
- Cyrstalloids and colloids should be rushed in the mean time. It enhances 
the critical filling and improves the cardiac output. 250 – 500 ml of 
either a crystalloid or a colloid is administered over a period of 10 – 20 
minutes as the urgency indicates. Cyrstalloids are preferred over colloids 
as they quickly become distributed throughout the extracellular space, 
they are cheap, easily available and there is no risk of anaphylaxis 
- Replace blood by blood 
- Invasive hemodynamic monitoring by CVP measurement 
- BT, CT should be measured and when it is prolonged FFP and 
cryoprecipitate should be given 
- The Non-Pneumatic Anti-Shock Garment (NASG) is a low-
technology first-aid device used to treat hypovolemic shock. It's efficacy 
for reducing maternal deaths due to obstetrical hemorrhage is being 
researched. When in shock, the brain, heart and lungs are deprived of 
oxygen because blood accumulates in the lower abdomen and legs. The 
NASG reverses shock by returning blood to the heart, lungs and brain. 
This restores the woman's consciousness, pulse and blood pressure. 
Additionally, the NASG decreases bleeding from the parts of the body 
compressed under it. 
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Medical management 
UTEROTONICS 
i) Oxytocin – 10 units im / iv followed by 20 units iv infusion in 500 ml 
RL / NS 
ii) Methylergometrine – 0.2 mg im / iv repeated for every 15 minutes to a 
maximum of 5 doses 
iii) 15 methyl PG F2α - 250 µgm im repeated every 15 minutes to a 
maximum of 8 doses 
iv) Misoprostol – 400 - 1000 µgm vaginal, oral, rectal 
v) Recombinant factor VIIa – 60 – 120 µgm / kg iv 
vi) Tranexamic acid – 1gm iv 8th hourly 
 Oxytocin stimulates the upper segment of the myometrium to contract 
rhythmically, which constricts the blood vessels and reduces blood flow 
through the uterus (Dreyfus M et al., 2004). Produces rhythmic uterine 
contractions, can stimulate the gravid uterus, and has vasopressive and 
antidiuretic effects. Can be used to control postpartum bleeding or 
hemorrhage. Some suggest its prophylactic use in the third stage of labor; 
one study of 1000 deliveries revealed a 32% reduction in the rate of PPH. 
Pierre F, Mesnard L, Body G Eur J Obstet Gynecol Reprod Biol. 1992. 
Side effects – hypotension if given by rapid iv bolus. Water intoxication 
with larger volumes. 
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 Methylergometrine – ergot alkaloids cause generalized smooth muscle 
contraction in which both upper and lower segments of the uterus. Side 
effects – hypertension, nausea, vomiting, headache.  
 Syntometrine – 5 units oxytocin + 0.5 mg ergometrine. 
 15 methyl PG F2α - enhances uterine contractility and causes 
vasoconstriction. It has been shown to control PPH in upto 81% of patients. 
Side effects – nausea, vomiting, diarrhea, hypertension, headache, flushing, 
pyrexia. Contraindications – hypersensitivity, bronchial asthma. 
 Misoprostol – it increases uterine tone. Side effects – hyperpyrexia, diarrhea, 
shivering. 
 Recombinant factor VIIa – it is an enzyme of the serine protease class. It 
initiates the process of coagulation in conjunction with tissue factor. 
(Ahonen et al., 2007). It induces haemostasis at the site of vascular injury 
independent of the presence of factors VIII and IX by forming complexes 
with exposed tissue factor (TF).  Administration of high-dose rFVIIa results 
in a huge increase in factor VIIa, well above that of the normal 
physiological levels, leading to faster and greater thrombin generation. 
 Anti fibrinolytics – Tranexamic acid potentates the blood clotting system 
and is used to treat and prevent bleeding. The mechanism of action of 
tranexamic acid is related to its antifibrinolytic effect, which makes this 
drug potentially very effective in the third stage of labour. During placental 
delivery, rapid degradation of fibrinogen and fibrin occurs, as well as an 
  
26 
increase in the activation of plasminogen activators and fibrin degradation 
products due to activation of the fibrinolytic system. This activation can last 
up to six to 10 hours postpartum, which may cause more haemorrhage.  The 
antifibrinolytic effect of tranexamic acid in the third stage of labour could 
make it a safe and effective alternative or adjunct to other regimens 
currently used in the third stage of labour for prevention of PPH. 
Tranexamic acid could reduce blood loss associated with complications 
such as placenta praevia and lower genital tract trauma, as well as bleeding 
from the upper segment placental site. Therefore, it may be particularly 
useful in preventing cases of PPH due to factors other than uterine atony, 
where uterotonics will not be effective. Tranexamic acid is an effective 
agent for the reduction of blood loss, which has been widely used in various 
areas of medicine. It is an inhibitor of fibrinolysis that blocks the lysine- 
binding site of plasminogen to fibrin (Astedt 1987; Longstaff, 1994). 
It has been used to decrease blood loss for many years in cases of 
haemorrhage, and is reported to reduce intraoperative and postoperative blood 
loss (Boylan, 1996; Karski, 1995; Katsaros, 1996; Reid, 1997; Vacharaksa, 
2002). 
The side effects described with the use of tranexamic acid include 
gastrointestinal symptoms such as diarrhoea, nausea and vomiting that occur in 
about 10% of patients. Rare complications include hypotension, thrombosis, 
blurred vision, renal cortical necrosis and retinal artery obstruction (Astedt, 
1987). 
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However, another study reported no side effects associated with 
tranexamic acid (Bekassy, 1990). 
A Cochrane review on the use of antifibrinolytics for heavy menstrual 
bleeding reported no rise in side effects with tranexamic acid in comparison to 
placebo, NSAIDS, oral luteal phase progestagens or ethamsylate (Lethaby, 
2000). 
There are concerns about the risk of thromboembolic events associated 
with the use of tranexamic acid; however, there are no data available from 
randomised controlled trials (RCTs) which record the frequency of 
thromboembolic events (Lethaby, 2000) as the fibrinolytic system gets 
activated after placental delivery and in menorrhagia, antifibrinolytics are 
useful in treating PPH and DUB. 
Single dose of 1 gm of tranexamic acid given intravenously reduces the 
mean blood loss within 2 hours of delivery (Pili ferrer et al., 2009). 
 Tranexamic acid significantly reduces the mean blood loss by 92 ml 
compared to no treatment (Gohel et al., 2007). 
Tranexamic acid reduces blood loss without any side effects or 
complications like thrombosis (Gai et al., 2004). 
 When tranexamic acid is used the need for additional uterotonic drugs is 
reduced (Gakhan Yildirim et al., 2011). 
 Tranexamic acid given at a dose of 10 mg / kg iv immediately after 
delivery of baby, reduces blood loss (Astedt et al., 1987). 
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Tranexamic acid acts immediately after iv administration (Jurema et al., 
2008). 
 Use of tranexamic acid could potentially have prevented some PPH 
cases, as reported in the Cochrane review in treatment of PPH (Mousa 2007) 
Tranexamic acid is associated with a significant reduction in objective 
measurement of heavy menstrual bleeding when compared to placebo or other 
medical therapies (Lethaby et al., 2000). 
Tranexamic acid is a cost effective drug. A study on total hip 
arthroplasty reported saving blood transfusion and money in cases where 
Tranexamic acid was used prophylactically prior to surgery (Johansson, 2005). 
 Blood loss of greater than 400 ml is not reported when Tranexamic acid 
is used during vaginal birth (Yang et al., 2001). 
Tranexamic acid is used safely and effectively to reduce bleeding 
resulting from caesarean section (Gai et al., 2004). 
Tranexamic acid statistically reduces the extent of bleeding from 
placental delivery to 2 hrs post partum during caesarean section and its use was 
not associated any side effects (Ming - Ying Gai et al., 2003). 
Tranexamic acid reduces blood loss and maternal morbidity in ongoing 
PPH (Anne – Sophie Ducloy et al., 2011). 
Tranexamic acid significantly reduces the amount of blood loss during 
and after caesarean section (Patel Purvi et al., 2007). 
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Tranexamic acid reduces post partum blood loss after vaginal birth and 
after caesarean section (Novikova N. et al., 2010). 
Tranexamic acid can be given antenatally by oral route for one week to 
treat women with history of recurrent abruption – to get successful neonatal 
outcome (B Astedt et al., 1978). 
Prophylactic tranexamic acid before surgery reduces allogenic blood 
transfusion (Cochrane database, 2001). 
Tranexamic acid can be used to decrease bleeding from menorrhagia 
and conisation of cervix (Dunn CJ et al., 1999). 
Tranexamic acid reduces mean blood loss after oral surgery in patients 
with hemophilia and it is effective as a mouth wash in dental patients receiving 
oral anti coagulants (Mairangi Bay et al., 1999). 
Tranexamic acid when given with in 3 hrs of trauma, mortality is 
reduced in trauma patients (Russel L Gruen et al., 2010). 
Tranexamic acid is an effective and safe option in DUB and operative 
interference is reduced (Kriplani A. et al., 2006). 
If bleeding persists even after removal of retained products of 
conception in missed abortion and secondary PPH, a fibrinolytic inhibitor such 
as tranexamic acid can be given to counteract fibrinolysis in uterus (J Bonner 
et al., 2011). 
Using tranexamic acid before caesarean section may reduce the blood 
loss as well. Use of tranexamic acid for preventing PPH may contribute to 
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reduction in blood product use, which is associated with multiple risks 
(transfusion reactions, transmission of blood-borne viruses), is expensive and 
may be not available when it is needed. In South Africa, most of the maternal 
deaths due to PPH occur in level one hospitals which do not have emergency 
access to formal blood transfusion services. 
WOMAN Trial 
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic 
acid for the treatment of postpartum haemorrhage: an international randomised, 
double blind placebo controlled trial. This is an ongoing trial. The results of 
which are expected in February 2015. 
Haleema Shakur1*, Diana Elbourne4, Metin Gülmezoglu2, Zarko 
Alfirevic3, Carine Ronsmans5, Elizabeth Allen4 and Ian Roberts1  
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This trial is a large, pragmatic, randomised, double blind, placebo 
controlled trial among 15,000 women with a clinical diagnosis of postpartum 
haemorrhage. All legally adult women with clinically diagnosed postpartum 
haemorrhage following vaginal delivery of a baby or caesarean section are 
eligible. The fundamental eligibility criterion is the responsible clinician's 
'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular 
woman with postpartum haemorrhage. Treatment entails a dose of tranexamic 
acid (1 gram by intravenous injection) or placebo (sodium chloride 0.9%) given 
as soon as possible after randomisation. A second dose may be given if after 30 
minutes bleeding continues, or if it stops and restarts within 24 hours after the 
first dose. 
Cost savings could also be gained from avoiding the use of expensive 
haematological agents such as Factor VIIa, which is establishing its place in the 
treatment of massive PPH in modern obstetrics despite the extreme cost 
(Welsh, 2008). 
 
SURGICAL MANAGEMENT 
• Bimanual compression 
• Uterine balloon tamponade 
• Compression sutures 
• Arterial ligation 
• Aortic clamping 
• Total / subtotal hysterectomy 
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A patient who fails to respond to uterotonic agents and continues to 
bleed will quickly become haemodynamically unstable and develop a cascade 
of clotting abnormalities. The spectre of maternal mortality can then only be 
prevented by initiating surgical haemostasis sooner rather than later. The 
nature, timing and extent of these invasive interventions will depend on the 
sophistication of the health facility which handles this medical crisis. The fate 
of such a woman will therefore vary widely, depending not only on where she 
lives in the world but also on where she lives in her own country. 
 
INTERVENTIONAL RADIOLOGY 
• Consider on stable patient with continued bleeding (Clinical textbook 
of obstetric and gynaecology 2010). 
• Evidence is equivocal (Greentop guidelines 2009). 
 Pelvic arterial embolsisation is a minimally invasive life-saving therapy 
that preserves patient quality of life and speeds recovery for patients with PPH. 
 
  
33 
PHARMACOLOGY OF TRANEXAMIC ACID 
Tranexamic acid is an antifibrinolytic drug. It is a synthetic derivative of 
the amino acid lysine that exerts its anti fibrinolytic effect through the 
reversible blockade of lysine binding sites on plasminogen molecules. 
 
CHEMICAL STRUCTURE 
 
 
 
Molecular formula : C8H15NO2 
It is a trans-4 aminomethyl cyclohexane 1-carboxylate 
Molecular weight : 157.21 
Melting point : 300oc 
Water solubility : 1 gm / 6 ml 
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Pharmacodynamics 
Fibrin is the basic framework for clot formation to maintain 
haemostasis. This clot has to be lysed after a particular period of time by 
fibrinolysis by the following way. 
 
   
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endothelial cell 
Thrombomodulin & Thrombin 
Protein C Activated protein C 
Activated VIII Inactive VIII Activated V Inactive V 
Inactivates inhibition of tissue plasminogen activator 
Plasminogen Plasmin 
Fibrinolysis 
FDP formation 
(-) 
TXA 
(-) 
TX
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Tranexamic acid acts as an antifibrinolytic agent by the following 2 ways: 
1. Reversible, competitive blockage of lysine binding sites on plasminogen, so 
that plasminogen activator cannot bind with plasminogen at lower doses. 
2. Non competitive inhibition of proteolytic action of plasmin similar to 
EACA. 8-10 times more potent than EACA as it binds strongly with both 
strong and weak receptors. 
At therapeutic concentration (1mg/ml) it will not cause platelet 
aggregation. 
 
Pharmacokinetics 
• Oral absorption is 30-50%. It is not affected by food 
• 100 % bioavailability with iv administration 
• Only 3% is plasma protein (globulin) bound. Remaining binds with 
plasminogen. It will not bind with serum albumin 
• Only 5% will be metabolized in liver. Remaining 95% of the drug will 
be excreted via urine unchanged 
• T ½  is 2- 10 hours. 90% of the drug is excreted in urine within 24 hours 
of administration. Duration of action in iv route is 7 – 8hrs 
• Rapidly enter into joint fluid 
• Crosses the placenta and blood brain barrier 
• 1% of serum level will be achieved in breast milk. 
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Indications 
This antifibrinolytic agent can be used in all types of bleeding especially 
coagulopathic bleeding. It can also be used prophylactically before surgical 
procedures where excess bleeding will be expected. 
1. HELLP, DIC, Thrombaesthenia related bleeding 
2. Postpartum haemorrhage 
3. Dental extraction in haemophilia patients 
4. Orthopaedic surgeries like spine surgery and total knee / hip 
replacement 
5. Caesarean section 
6. Cardiac surgeries 
7. Trans urethral resection of prostate 
8. Epistaxis 
9. Liver transplantation surgery 
10. First line nonhormonal treatment for menorrhagia in DUB / fibroid 
11. Hereditary angioneurotic oedema where it decreases the attacks by 
decreasing plasmin induced complement activation. 
 
Contraindications 
1. Previous H/O thromboembolism or active intravascular clotting or 
patients with inherited or acquired thrombophiliac states. 
2. Renal failure 
3. Liver failure 
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4. Patients with defective colour vision 
5. Subarachnoid haemorrhage – because cerebral oedema and infarction 
may occur rarely. 
Side effects 
1. Nausea, vomiting, diarrhoea – commonest side effect, occurs in > 10% 
cases 
2. Giddiness and hypotension – if given by sudden rapid iv occurs in 1-
10% of cases 
3. Defective colour vision – if used for long time 
4. Thromboembolism – rare 
5. Drug allergy – rare 
 
Monitoring 
LFT, RFT and colour vision should be checked periodically if used for 
long time. 
 
Should be used with caution in, 
1. Drug allergy patients 
2. Renal / liver disease patients 
3. Elderly individuals with impaired renal function 
4. Pregnancy – as this is a category B drug, Tranexamic acid can be safely 
used in lactating mothers, because 
• 1% of maternal serum level will be reached in breast milk 
• Only 30-50% absorption occur orally 
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PREPARATIONS AND DOSAGE 
1. Oral - 500 mg tablets available  
- 25 mg / kg thrice daily for one week 
2. Intravenous 
• Available preparations contain 100 mg / ml (5ml and 10ml ampoules)  
• Dose – 10 mg /kg either direct slow IV or after diluting with 20 ml of 
5% dextrose at a rate not more than 1 ml / min. This loading dose can be 
followed by 1mg / kg / hour IV infusion or 10 mg / kg – thrice daily IV.  
• It can be mixed with aminoacids, electrolytes or carbohydrate solution 
but not with blood or solutions having penicillin. 
3. Mouthwashes containing tranexamic acid are also available and used for 
haemophilia patients before and after dental extraction because oral mucosa 
and saliva are rich in plasminogen activator. 
* Dose should be adjusted according to creatinine clearance, creative clearance  
50 – 80 ml / min - 50% of total dose 
10-50 ml/min - 25% of total dose 
< 10 ml / min - 10% of total dose 
 
Storage 
Should be stored at 25oC (Room temperature) in a cool, dry place and 
should be kept away from heat or sunlight. 
  
39 
Drug Interactions 
1. Chlorpromazine increases cerebral vasospasm when combined with 
Tranexamic Acid, so it should not be combined. 
2. Factor IX when given along with Tranexamic Acid there will be 
increased thrombosis risk. So it should not be combined. 
  
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
 
 
The subjects of this prospective randomised placebo controlled study 
were 200 pregnant women who were admitted in the labour ward of Annal 
Gandhi Memorial Government Hospital – Trichy, in the time period from July 
2010 to July 2011. 
In all patients detailed history – medical history, obstetric history were 
taken. Vital parameters checked and basic investigations done. Weight of the 
patient checked. Detailed general examination and obstetric examination done. 
Gestational age confirmed by USG.  100 patients were placed in study group 
and 100 patients were placed in control group.  All patients were counselled 
and informed consent obtained. 
Study group received 
1. Oxytocin 10 units im within 1 minute of delivery. 
2. Inj. Tranexamic acid 10 mg / kg slow direct iv over 5 minutes period at 
delivery of anterior shoulder. 
Control group received 
1. Oxytocin 10 units im within 1 minute of delivery. 
2. Placebo injection of normal saline 5 ml slow direct iv over 5 minutes 
period at delivery of anterior shoulder. 
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Inclusion Criteria 
1. Primi and 2nd gravida 
2. More than 38 weeks of gestation. 
3. spontaneous / induced labour 
 
Exclusion Criteria 
Women with risk factors for PPH were not included in this study. 
1. Haemoglobin < 8gm% 
2. Twin pregnancy 
3. Polyhydramnios 
4. EFW > 4 kg 
5. Previous H/O PPH 
6. Fibroid complicating pregnancy 
7. Preeclampsia 
8. Placenta previa 
9. Abruptio placenta 
10. Prolonged and obstructed labour 
11. Heart disease complicating pregnancy 
12. Renal / liver disease patients 
13. Patients on anticoagulants 
14. Previous H/O thromboembolism 
15. Gravidity ≥ 3 
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Methods 
Study group and Control group patients received the injections as above 
mentioned. In each case the following parameters were noted. 
1. Predelivery PR, BP, RR, SpO2, urine output in ml / hr, Hb gm%, PCV% 
was noted. 
2. Blood loss from delivery of the baby to 2hrs post partum was noted.  
3.  The Apgar scores was noted 
4. Side effects of the drug was noted 
5. Post partum  PR, BP, RR, SpO2, urine output in ml / hr, Hb gm%, 
PCV% was noted 
6. Maternal needs for blood transfusion was noted. 
7. Maternal outcome till discharge was noted. 
 
Measurement of Blood loss 
Immediately after delivery of the baby, when all the liquor was drained, 
the patient was brought to the edge of the table. The patient was placed over a 
blood drape, a disposable, conical, graduated plastic collection bag. 
The amount of blood collected in the blood drape is measured. Then the 
patient was given pre-weighed pads, which was weighed 2 hrs postpartum. In 
our study blood loss was measured by measuring the blood collected in the 
drape and by weighing the swabs before and after delivery. 
Total blood loss (ml) =   blood in the drape (ml) 
+  
(swab weight postdelivery in gms – swab weight predelivery in gms) 
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After collecting all the data, the data were tabulated in a master chart 
and analysed. The collected questionnaire from the respondents was analysed 
by using the Statistical Package for Social Sciences (SPSS) ver 13.0. Using 
this software frequencies, percentage, mean, Standard Deviation, chi square 
and ‘p’ values were calculated.  A ‘p’ value less than 0.05 is taken to denote 
significant relationship. 
 
Standard Deviation 
 Standard deviation is defined as the square root of the arithmetic mean 
of the squared deviations of the various items from arithmetic mean.  
 Standard Deviation, σ = 
2Σd
N
 
where, 
 X - variable 
 σ - standard deviation 
 X  - mean of the variable X = iX
n
 
 di  - X - X  
 
Pearson’s Correlation Coefficient 
 p = 
( )( )
( ) ( )
i i
2 2
i i
Σ x - x y - y
Σ x - x y - y
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where 
 p - correlation coefficient 
 xi - value of ith item of variable x 
 x  - mean of variable x 
yi - value of ith item of variable y 
y  - mean of variable y 
Σ - sum 
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RESULTS AND ANALYSIS 
 
TABLE - 1 
AGE 
Number  of Cases 
Study Group Control Group Age in Years 
Number % Number % 
< 20 06 6% 06 6% 
20 – 24 48 48% 52 52% 
25 – 29 40 40% 36 26% 
≥ 30 06 6% 06 6% 
Mean 24.60 24.10 
SD 3.43 3.44 
P 0.5890  (P > 0.05) (NS) 
 
The mean age of the cases in both the groups doesn’t differ 
significantly. 
Majority of the patients (50%) belonged to 20-24 years.  
And on an average 6% of the patients belong to <20 and ≥30 years. 
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TABLE – 2 
SOCIOECONOMIC STATUS 
Number of Cases 
Study Group Control Group Socioeconomic Status 
Number % Number % 
V 76 76 72 72 
IV 24 24 28 28 
S. D. 0.503 0.441 
P 0.410 (NS) 
 
 In our study no patient belonged to the class I, II or III socioeconomic 
status. 
Majority of the patients were under the class V socioeconomic status. 
And there was no significant difference between the groups. 
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TABLE – 3 
OBSTETRIC FORMULA 
Number of Cases 
Study Group Control Group Obstetric formula 
Number % Number % 
Primi 20 20 30 30 
2nd gravida 80 80 70 70 
SD 0.435 
P 0.718 (NS) 
 
20 patients in study group and 30 patients in control group were primi 
gravida. 
80 patients in study group and 70 patients in control group were 2nd 
gravida. 
Parity index was comparable in both the groups. 
FIG. 3 
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TABLE – 4 
BOOKING STATUS 
Number of Cases 
Study Group Control Group Booking Status 
Number % Number % 
Booked 80 80 84 84 
Unbooked 20 20 16 16 
SD 0.412 0.419 
P 0.603 (NS) 
 
Antenatal booking doesn’t differ in both the groups significantly. 
20% of the patients in study group and 16% of the patients were 
unbooked. 
FIG. 4 
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TABLE – 5 
SUBJECTIVE CHARACTERS 
Study group Control group 
Subjective characters 
Mean S.D. Mean S.D. 
P 
Weight (kgs) 55.18 1.71 55.16 1.69 0.219* 
Height (cms) 154.12 1.78 153.80 1.71 0.436* 
BMI 23.23 0.63 23.32 0.63 0.299* 
* (P > 0.05) (NS) 
The average weight was 55.18kg in the study group and 55.16kg in the 
control group. 
The average height was 154.12cm in the study group and 153.80cm in 
the control group. 
The average BMI was 23.23kg/m2 in the study group and 23.32kg/m2 in 
the control group. 
Subjective characters were comparable between the two groups. 
FFIG. 5 
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TABLE – 6 
CHANGES IN VITAL PARAMETERS 
Number of cases 
Study group Control group Parameters 
Mean S.D. Mean S.D. 
 
P 
PULSE RATE / MIN      
Pre delivery 82.38 2.79 82.86 2.60 
Post delivery 83.86 2.64 88.24 2.61 
Change +1.48  +5.38  
0.0001 (S) 
SYSTOLIC BP MM HG      
Pre delivery 117.52 5.65 108.68 5.61 
Post delivery 116.40 5.34 104.92 5.29 
Change -1.12  -3.76  
0.0001 (S) 
DIASTOLIC BP MM HG      
Pre delivery 76.80 8.87 76.92 8.47 
Post delivery 76.34 8.78 73.64 8.88 
Change -0.46  -3.28  
0.0001 (S) 
RESPIRATORY RATE / 
MIN      
Pre delivery 17.93 0.30 17.80 0.31 
Post delivery 18.14 0.98 18.06 1.07 
Change -0.21  -0.26  
0.147(NS) 
SPO2 %      
Pre delivery 99.90 12.09 99.90 10.13 
Post delivery 99.66 11.94 98.79 9.64 
Change -0.24  -1.11  
0.0001 (S) 
URINE O/P ML / HR      
Pre delivery 108.10 2.02 109.70 2.12 
Post delivery 106.90 1.97 106.50 1.86 
Change -1.20  -3.20  
0.167(NS) 
 
  
51 
Mean increase in pulse rate was 1.48/min in study group and 5.38/min in 
control group. 
Mean fall in systolic BP was 1.12mmHg in study group and 3.76mmHg 
in control group. 
Mean fall in diastolic BP was 0.46mmHg in study group and 3.28mmHg 
in control group. 
Mean increase in respiratory rate was 0.21/min in study group and 
0.26/min in control group. 
Mean fall in spO2 was 0.24% in study group and 1.11% in control group. 
Mean fall in urine o/p was 1.20ml/min in study group and 3.20ml/min in 
control group. 
PR increases and BP decreases significantly in control group compared 
with that of study group.  
And the post delivery spO2 was better in the study group. 
FIG. 6 
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TABLE – 7 
CHANGES IN BLOOD INDICES 
Study group Control group 
Blood indices 
Mean S. D Mean S. D 
P 
HB GM %      
Pre delivery 8.86 1.78 8.88 1.93 
Post delivery 8.84 1.77 8.73 1.91 
Change -0.02  -0.15  
0.0001(S) 
PCV %      
Pre delivery 39.04 7.04 38.72 4.56 
Post delivery 38.70 7.01 37.62 4.53 
Change -0.34  -1.10  
0.0001(S) 
 
Mean fall in haemoglobin was 0.02gm% in study group and 0.15gm% in 
control group. 
Mean fall in hematocrit was 0.34% in study group and 1.10% in control 
group. 
The post delivery haemoglobin and hematocrit was significantly reduced 
in the control group compared to the study group. 
Fig. 7 
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TABLE – 8 
ONSET OF LABOUR 
Number  of   cases 
Study  group Control group Onset of labour 
Number % Number % 
Spontaneous 52 52 56 56 
Induced 48 48 44 44 
SD 1.432 1.889 
P 0.413 (NS) 
 
Majority of the patients (54%) had spontaneous onset of labour. 
And there was no significant difference between the groups. 
FIG. 8 
ONSET OF LABOUR 
52
56
48
44
0
10
20
30
40
50
60
N
o
.
 
o
f C
a
s
e
s
Spontaneous Induced
Onset of Labour
Study Group Control Group
 
  
54 
 
 
TABLE – 9 
MODE OF DELIVERY 
Number  of   cases 
Study  group Control group Mode of delivery 
Number % Number % 
Labour natural 72 72 60 60 
Labour natural with 
episiotomy 22 22 36 36 
Labour natural with 
lacerated perineum 06 06 04 04 
SD 2.705 2.998 
P 0.631 (NS) 
 
Majority of the patients (66%) had labour natural. 
And there was no significant difference between the groups. 
FIG. 9 
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TABLE – 10 
CHANGES IN DURATION OF THIRD STAGE 
Duration of 3rd stage in 
minutes Study group Control group 
Mean 4.6 4.48 
S.D. 1.428 1.854 
P 0.141 (NS) 
 
The mean duration of 3rd stage was 4.6mins in the study group and 
4.48mins in the control group. 
There was no influence of the drug in the duration of 3rd stage. 
FIG. 10 
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TABLE – 11 
BLOOD LOSS 
Study group Control group 
Blood loss in ml 
Mean S.D. Mean S.D. 
P 
Time of delivery to 30 mins 81.01 50.387 191.65 49.884 0.0001(S) 
30 mins to 2 hrs 27.27 6.17 51.72 9.78 0.0001(S) 
Time of delivery to 2 hrs 108.27 58.570 247.37 58.070 0.0001(S) 
 
The mean blood loss at the end of 2 hrs was 108.27 ml in study group 
and 247.37 ml in the control group. 
The blood was significantly low in the study group compared to the 
control group during all periods. 
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TABLE – 12 
ADDITIONAL UTEROTONICS 
Study group Control group 
Additional uterotonics 
Number % Number % 
Yes 2 2 22 22 
No 98 98 78 78 
P 0.002 
 
22% of the patients in the control group needed additional uterotonics 
compared to only 2% in the study group. 
There was a significant difference in the requirement of uterotonics 
between the groups. 
2 patients in the study group needed additional uterotonics (carboprost 
and methergin) and both needed blood transfusion. 
22 patients in the control group needed additional uterotonics, of which 
10 had PPH and other 12 had mild atonicity. 
All the 22 patients were given 250 µg carboprost – PGF2α im. 
8 patients responded to carboprost. 
14 patients needed injection methergin 0.2 mg IV, of which 4 responded 
and 10 needed per rectal misoprostol 800 µg and blood transfusion. 
FIG. 12 
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TABLE – 13 
MATERNAL BLOOD TRANSFUSION 
Study group Control group 
Blood transfusion 
Number % Number % 
Yes 02 02 10 10 
No 98 98 90 90 
Chi-Square Value 0.092 0.207 
P 0.0102 (S) 
 
10% of the patients in the control group needed blood transfusion 
compared to 2% in the study group. 
There was a significant difference in the need for blood transfusion 
between the groups. 
FIG. 13 
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TABLE – 14 
MATERNAL COMPLICATIONS 
Study group Control group 
Complications 
Number % Number % 
Vomiting 6 6 6 6 
Fever 4 4 6 6 
Nil 90 90 88 88 
Chi-Square Value 0.211 0.213 
P 0.41 (NS) 
 
There was no significant difference in maternal complications between 
the groups. 
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TABLE – 15 
APGAR SCORES 
Study group Control group 
Apgar scores 
Number % Number % 
≥ 8 / 10 96 96 94 94 
< 8 / 10 04 04 06 06 
Chi-Square 0.211 0.212 
P 0.500 (NS) 
 
The apgar scores was not found to be influenced by the use of the drug. 
There was no statistical difference between the groups. 
FIG. 15 
APGAR SCORES 
6 6
4
6
90 88
0
10
20
30
40
50
60
70
80
90
N
o
.
 
o
f C
as
es
Vomiting Fever Nil
Complications
Study Group Control Group
 
  
61 
 
 
 
TABLE – 16 
DURATION OF STAY 
Study group Control group 
Duration of stay 
Number % Number % 
≤ 3 days 98 98 88 88 
>  3 days 02 02 12 12 
Chi-square 1.895 2.022 
P 0.041 (S) 
 
12% of the patients in the control group had to stay for more than 3 days 
compared to 2% in the study group. 
FIG. 16 
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DISCUSSION 
 
As obstetric blood loss contributes to one fourth of global maternal 
death, death resulting from PPH should be avoided. As the fibrinolytic system 
gets activated after placental delivery antifibrinolytic agents can be used to 
reduce obstetric blood loss. 
As prevention is always better than cure regarding PPH- an 
antifibrinolytic agent tranexamic acid was used prophylactically in our study to 
observe its efficacy in reducing blood loss during and after vaginal birth. 
1. Maternal age 
In our study, the age group of patients included varied from 18 to 35 
years. Maximum percentage of patients belong to the age group of 20-24 years. 
48% of study group and 52% control group were between 20-24 years. In a 
study conducted by Yang H, Shi C-Department of Obst & Gynaecology, first 
teaching hospital of Beijing University, Beijing, China in 2001 october - the 
mean age was 23.5 years. 
2. Socio economic status 
In our study 76% of study group and 72% of control group belonged to 
class V socioeconomic status. 24% of the study group and 28% of the control 
group belonged to class IV socioeconomic status. In a study conducted by the 
department of obstetrics and gynaecology – Ayub medical college, Pakistan, by 
Shamshad Bibi et al in 2009, 74% in the study group and 76% in the control 
group belonged to class V socioeconomic status. 
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3. Obstetric formula 
In our study, second gravida were more in both groups than 
primigravida. All were Singleton pregnancies. In the study group 20% were 
Primigravidas and 80% were 2nd gravidas. In the control group 30% were 
Primigravidas and 70% were 2nd gravidas. In a similar study conducted by 
Yildrium M.D at Erzincan military hospital, Turkey in april 2011 - second 
gravidas were 72% and primigravidas were 28%. 
4. Booking status 
In our study, 80% of study group and 84% of Control group were 
booked. 20% of study group and 16% of control group were unbooked. In a 
similar study conducted by Panagiotis and Rezan from Department of 
Obstetrics and Gynaecology, London in march 2011, 86% of study group and 
88% of control group were booked. Proper antenatal care is important to 
identify the high risk factors in the antenatal period itself and to correct them 
thereby reducing the incidence of PPH. 
5. Subjective characters 
In our study mean height was 154.12 cm in study group and 153.80 cm 
in control group. Mean weight was 55.18 kg in study group and 55.16 kg in 
control group. Mean BMI was 23.23kg/m2 in study group and 23.32kg/m2 in 
control group. In a similar study conducted by Shanghai International Pence 
maternity and child health hospital, Shanghai, China – mean height was 153 cm 
and mean weight was 62 kg. 
  
64 
6. Change in Vital parameters 
In our study, mean post delivery increase in PR was 1.48 in study group 
and 5.38 in control group. Mean fall in SBP was 1.12 in study group and 3.76 
in control group. Mean fall in DBP was 0.46 in study group and 3.28 in control 
group. Mean increase in RR was 0.21 in group A and 0.26 in group B. mean 
fall in spO2 was 0.24% in the study group and 1.11% in the control group. 
Mean fall in urine output was 1.20ml in the study group and 3.20ml in the 
control group and was not statistically significant. There was a significant fall 
in SBP and rise in PR without any significant change in RR. In a similar study 
conducted by Natalia Novikova et al in 2010, there was a statistically 
significant change in vital parameters. 
7. Changes in blood indices 
In our study statistically significant fall in Hb% occurred after delivery 
in control group than with study group. Mean fall of Hb% was 0.02gm% in 
study group and 0.15gm% in control group. Mean fall in hematocrit was 
0.34% in the study group and 1.10% in the control group. In a study conducted 
in the Department of obstetrics and gynaecology, University of Manitoba, 
2010, statistically significant drop in haemoglobin was observed in the control 
group. 
8. Onset of labour 
In our study 48% in study group had induced labour and 44% in control 
group had induced labour. Both the groups were comparable. 
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9. Mode of delivery 
In our study 72% in the study group and 60% in the control group had a 
labour natural, 22% in the study group and 36% in the control group had labour 
natural with episiotomy, 6% in the study group and 4% in the control group 
had lacerated perineum. Both the groups were comparable in al three modes of 
delivery. 
10. Changes in duration of 3rd stage of labour 
The mean duration of third stage was 4.6mins in the study group and 
4.48 mins in the control group. There was no statistical difference between the 
groups. Duration of third stage is not altered on adding the drug. 
11. Blood loss 
In our study, there was a statistically significant reduction of blood loss 
in both periods, that is from time of delivery to 30 mins and also from 30 mins 
to 2 hrs postpartum. Mean blood loss from time of delivery to 30 mins was 
81.01 ml in study group and was 191.65 ml in control group. Mean blood loss 
from 30 mins to 2 hour post partum was 27.27 ml in study group and 51.72 ml 
in control group. Mean total blood loss was 108.27 ml in study group and 
247.37 ml in control group.  In a study conducted at the Centre Hospitalier 
Regional Universitaire, France in 2010, the mean total blood loss in the study 
group was 120ml compared to 232.45ml in the control group.  
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12. Additional uterotonics 
In our study, 22% of the patients in the control group needed additional 
uterotonics compared to only 2% in the study group. The drug significantly 
decreases the need for additional uterotonics. In a study conducted by Leila 
Shekhavat et al 2009, Department of obstetrics and gynaecology, Shahid 
Sedughi Hospital / Shahid Sedughi University of medical sciences and health 
services, Yazd, Iran – only 4% in the study group needed additional 
uterotonics. 
13. Maternal blood transfusion 
In our study, only 2% in the study group compared to 10% in the control 
group needed blood transfusion. This result was also observed in a similar 
study conducted by the Division of Obstetrics and gynaecology, University of 
Oslo, Norway in 2009. 
14. Maternal complications 
In our study, 6 patients in study group and 6 patients in control group 
had vomiting which may be related to the drug. But this incidence of vomiting 
in study group was not statistically significant. 4 patients in study group and 6 
patients in control group had fever. 3 of the study group patients with fever 
had LRI and was treated with antibiotics and discharged on 5th PND. Among 6 
patients, who had fever in control group 4 had LRI and 2 had breast 
engorgement as their babies was admitted in NICU. None of the patients in 
both groups had thromboembolic complications postnatally. 
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15. Apgar scores 
In our study, the apgar scores were comparable in both groups.  3 babies 
in study group needed NICU admission for HIE stage I. 4 babies in group B 
needed NICU admission for HIE Stage I and two babies had sepsis. The 
inference was that tranexamic acid use was not associated with any impact on 
neonatal outcome in our study.  In a similar study conducted by Department of 
Obs & Gyn King’s College hospital, London, there was no significant 
difference in the Apgar scores between study and control groups. 
16. Duration of stay 
2 patients in the study group had to stay for more than 3 days as they 
were anemic and needed blood transfusion and parenteral iron.  10 patients in 
the control group were anemic and were transfused blood and given parenteral 
iron.  And 2 more patients in the control group were not discharged as they had 
fever with breast engorgement. 
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SUMMARY 
 
• This study was conducted in the Department of Obstetrics and 
Gynaecology, Annal Gandhi Memorial Government Hospital, Trichy to 
clinically observe the blood loss reduced by tranexamic acid during 
normal labour. 
• 200 patients were selected for the study, 100 as study group and 100 as 
Control group. 
• 50% of the cases belonged to the age group 20 – 24 years. 
• 74% of the cases belonged to class V socioeconomic status. 
• 25% of the cases were primigravida and 75% of the cases were 2nd 
gravida. 
• 82% of the cases were booked cases. 
• There was no statistically significant difference in the subjective 
characters in between the two groups. 
• There was statistically significant fall in blood pressure and rise in PR 
without any significant change in RR in the control group compare to 
the study group. 
• Hb level and hematocrit was significantly reduced in the control group 
compared to the study group. 
• Tranexamic acid significantly reduced the blood loss from the time of 
delivery to 2 hour post partum. 
  
69 
• The need for additional uterotonics and maternal blood transfusion is 
significantly reduced in the study group compared to the control group. 
• The incidence of vomiting, shivering, fever were statistically insignificant. 
• None of the patients in both the groups had thromboembolic complications 
postnatally. 
• The apgar scores and neonatal outcome was similar in both the groups. 
• The duration of stay was found to be reduced in the study group when 
compared to the control group. 
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CONCLUSION 
 
Tranexamic acid injection, an antifibrinolytic agent when given 
prophylactically at the delivery of the anterior shoulder, by intravenous route 
appears to reduce the blood loss during normal labour effectively. Some 
studies demonstrated that tranexamic acid minimally increases the risk of 
thromboembolism but without statistical significance which was not observed 
in our study. So, further studies are also needed to support its efficacy. 
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INFORMATION SHEET FOR THE PATIENT AND HER REPRESENTATIVE(S) 
We welcome you and thank you for your keen interest in participation in 
this research project. Before you participate in this study, it is important for 
you to understand why this research is being carried out. This form will 
provide you all the relevant details of this research. It will explain the nature, 
the purpose, the benefits, the risks, the discomforts, the precautions and the 
informations about how the project will be carried out. It is important that you 
read and understand the contents of the form carefully. This form may contain 
certain scientific terms and hence, if you have any doubts or if you want more 
information, you are free to ask the study personnel or the contact person 
mentioned below before you give your consent and also at any time during the 
entire course of the project. 
1. Project title 
Role of tranexamic acid in reducing blood loss in normal labour. 
2. Department and institute 
Department of obstetrics and gynaecology, K.A.P. VISWANATHAN 
GOVERNMENT MEDICAL COLLEGE, TRICHY 
3. Name of the investigator 
Dr. B. Sowmya 
4. What is the purpose of this project / study? 
To compare the efficiency of tranexamic acid and oxytocin with only 
oxytocin in reducing the amount of bleeding after delivery. 
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5. What is the selection procedure of participants? 
Inclusion Criteria: Primi and 2nd gravid, More than 38 weeks of 
gestation, spontaneous / induced labour 
Exclusion Criteria: Haemoglobin < 8gm%, Twin pregnancy, Polyhydramnios, 
EFW > 4 kg, Previous H/O PPH, Fibroid complicating pregnancy, Preeclampsia, 
Placenta previa, Abruptio placenta, Prolonged and obstructed labour, Heart 
disease complicating pregnancy, Renal / liver disease patients, Patients on 
anticoagulants, Previous H/O thromboembolism, Gravidity ≥ 3. 
 
6. What is the procedure of the study? 
Both the study group and the control group will be placed on a 
calibrated obstetric drape during the delivery. The Study group will receive 
Oxytocin 10 units im within 1 minute of delivery and Inj. Tranexamic acid 10 
mg / kg slow direct iv over 5 minutes period at delivery of anterior shoulder. 
and the  control group will receive Oxytocin 10 units im within 1minute of 
delivery and Placebo injection of normal saline 5 ml slow direct iv over 5 
minutes period at  delivery of anterior shoulder. Predelivery vital parameters 
will be noted. Pre-weighed pads will be given to the participants. And it has to 
be returned to the investigator immediately 2 hrs after delivery. These pads will 
be weighed immediately to assess the amount of blood loss. And the total 
amount of blood loss will by adding the blood in the drape and in the pads. 
Post- delivery vital parameters will be noted.  Side effects of the drug if any 
will be noted. 
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7. What are the responsibilities of the participants? 
The patients will be given the drug immediately after delivery. The 
participants are expected to use only the pre-weighed diapers given by the 
investigator and hand over the soiled diapers immediately 2 hrs after delivery. 
 
8. What are the expected risks for the participants? 
Tranexamic acid is NOT a new drug and it is widely used to reduce 
bleeding in conditions such as major heart surgery. There is no conclusive 
evidence of serious side effects with short term use. But the study treatment 
may cause clots where they are not needed and, because the drug is not 
routinely used after childbirth, we do not know all the likely side effects. 
According to the studies which are previously done, expected risks are very 
minimal, like shivering, vomiting and giddiness. 
 
9. What are the expected benefits of the study to the participants? 
The amount of blood loss will be reduced. Hence the need for blood 
transfusion will be reduced. The participant will not suffer from anemia during 
the post partum period. The duration of stay in the hospital is also reduced. 
 
10. Will the participant be compensated for participation in this trial? 
No 
 
11. Whether any participation in this study be kept confidential? 
Yes 
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12. Can I withdraw from the study at any time during the study period? 
Yes 
 
13. If there is any new findings / informations, would I be informed? 
Yes 
 
14. What happens in case of a study related injury? 
Study related injuries are found to be very minimal 
 
15. Is there any alternative to the treatment mentioned? 
Yes they are available. But it is very expensive (recombinant factor VIIa). 
 
16. Are there costs associated with this research study? Will I receive 
any payments?  
 
This study is done free of cost to the participant, however you will not 
receive compensation of any kind for your participation in this research. 
For any study related queries, you are free to contact. 
Name of the contact person with official address: Dr. B.Sowmya, junior 
resident, department of obstetrics and gynaecology, K.A.P. VISWANATHAN 
GOVERNMENT MEDICAL COLLEGE, TRICHY.  
 
Place: Trichy     Signature of the investigator : 
Date :   Witness : 
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CONSENT FORM FOR THE PATIENT 
1. I confirm that I have read and understood the information sheet for the 
study and have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason and without my 
medical care or legal rights being affected. 
3. I understand that sections of my medical notes and those of my baby/ies 
may be looked at by responsible individuals involved in the study. I give 
permission for these individuals to have access to these records. 
4. I give permission for my personal doctor to be given information about 
my participation in this trail. 
5. I agree to take part in this study. 
 
Name of the patient :   Date :  
Signature / Thumbprint :  
 
Name of the person taking consent :     Date : 
Signature : 
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INVESTIGATOR'S AND/OR ASSOCIATE'S STATEMENT 
 
I have fully explained to ______________________________________ 
[participant / parent / guardian] the nature and purpose of the above-described 
procedures and the risks involved in its performance. I have answered and will 
answer all questions to the best of my ability. I will inform the participant of 
any changes in the procedures or the risks and benefits if any should occur 
during or after the course of the study.  
 
 
 
Date (MM/DD/YEAR)  Signature of Investigator or Associate 
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PROFORMA 
Name  :      Age  :   IP NO  : 
Socio Economic Status :  I II III IV V 
Date of admission  : 
Obstetric formula  :   G  P    L    A 
Booking status  : Booked   /                   Unbooked 
Past history    :  
Obstertric history  : 
 
General examination 
Height  :  Weight  :   BMI  : 
PR / min  :                         SpO2 :    
BP / mmhg  :        Urine o/p in ml / hr : 
RR / min  :  
CVS  : 
RS  : 
Abdominal examination  : 
Vaginal examination  : 
 
Basic investigations 
Urine  : albumin -  sugar - deposits - 
Hb gm%  :  Urea   :  
PCV %  :  Sugar  :  
LFT  :  Creatinine  : 
Blood group  : 
Onset of labour  : Spontaneous                      Induced 
Mode of delivery  : LN             LN Ĉ EPI              LN Ĉ LP 
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Duration of third stage in minutes  : 
Blood loss (ml)   : Delivery to 30 mins –  
  : 30 mins to 2 hrs –  
   : Total blood loss –  
Additional uterotonics  : YES             NO 
 
2 Hrs postpartum  
PR / min  :                                 SpO2 :    
BP / min  :  Urine output in ml / hr : 
RR / min  :  
48 hrs postpartum  :  Hb gm% -   PCV % -  
Maternal transfusion  :  YES                      NO 
Maternal complications  :  
5 min apgar   : ≥ 8/10                < 8/10 
Date of delivery  : 
Duration of hospital stay  : 
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S1 19 24390 V PRIMI UB 152 53 22.93 80 112/70 17 99 100 8.4 36 S LN Ĉ E 5 72.5 23 95.5 no 82 110/70 20 99 100 8.4 35 no nil no no 
S2 20 27589 IV G2P1L1 B 152 55 23.80 80 120/70 18 100 120 8.8 38 S LN 5.5 75 24.5 99.5 no 82 120/70 18 100 110 8.8 38 no nil no no 
S3 32 28595 V G2A1 B 154 54 22.76 82 126/76 18 100 100 8.8 38 S LN Ĉ E 4.36 75 25.5 100.5 no 82 120/70 18 100 100 8.8 38 no nil no no 
S4 22 20956 IV G2P1L1 B 155 53 22.06 84 110/70 18 100 125 8.4 36 S LN 5.5 75 24.5 99.5 no 86 108/70 18 100 125 8.2 34 no nil no no 
S5 25 24435 V G2P1L1 B 152 54 23.37 82 122/80 18 100 100 9 38 S LN 6 75 23 98 no 82 120/80 18 100 100 9 38 no nil no no 
S6 24 24467 IV PRIMI UB 153 55 23.49 82 120/70 17 99 100 8.8 38 I LN Ĉ E 4.36 75 25 100 no 84 120/70 17 100 100 8.8 38 no nil no no 
S7 29 26789 V G2A1 B 152 53 22.93 74 120/80 18 100 130 8.6 38 S LN Ĉ LP 5.3 75 24.5 99.5 no 75 120/80 18 100 130 8.6 38 no nil no no 
S8 21 34567 V G2P1L1 B 153 54 23.06 84 110/70 16 100 120 8 36 S LN 5.23 75 26 101 no 86 110/70 16 100 120 8 34 no nil no no 
S9 26 35678 V PRIMI B 156 56 23.01 80 110/80 18 100 130 8.8 40 S LN Ĉ E 4.2 75 26.5 101.5 no 82 110/80 19 100 130 8.8 40 no nil yes no 
S10 23 32414 V G2P1L1 UB 154 53 22.34 82 116/70 19 100 120 9.2 40 I LN 5.36 75 24.5 99.5 no 82 110/70 19 100 120 9 40 no vomiting no no 
S11 28 35643 V G2P1L1 B 152 56 24.23 84 116/80 17 100 100 9.2 40 S LN 6 75 23 98 no 84 116/80 17 100 100 9.2 40 no nil no no 
S12 24 37843 V G2P1L1 B 155 55 22.89 86 120/70 18 100 130 8.8 38 S LN 4.36 75 24 99 no 88 120/70 18 100 130 8.8 38 no nil no no 
S13 24 38921 V PRIMI UB 158 59 23.63 78 110/70 18 99 100 9.4 42 S LN Ĉ E 4.35 76 25 101 no 80 110/70 18 100 100 9.4 42 no nil no no 
S14 22 39908 V G2P1L1 UB 152 54 23.37 84 120/80 19 99 125 8.6 36 S LN 5.25 78 23 101 no 84 120/80 19 99 125 8.6 34 no nil no no 
S15 27 34564 V G2A1 B 154 53 22.34 80 122/80 18 100 100 10 42 I LN Ĉ E 5.3 74.5 24.5 99 no 82 122/80 17 100 100 10 42 no nil no no 
S16 23 45634 V PRIMI B 156 57 23.42 82 120/70 19 100 110 9.2 40 S LN Ĉ LP 4.18 73.5 23 96.5 no 84 120/70 19 100 110 9.2 40 no nil no no 
S17 35 47687 V G2P1L1 B 152 53 22.93 84 112/70 18 100 100 9.1 38 I LN 4 73 25.5 98.5 no 86 112/70 18 100 100 9 38 no nil no no 
S18 21 47854 V PRIMI B 156 55 22.6 80 112/70 17 100 125 8.5 37 I LN Ĉ E 4.21 76 23 99 no 81 110/70 17 100 125 8.5 37 no nil no no 
S19 29 46968 V PRIMI B 155 54 22.47 80 110/70 18 100 100 9.1 39 S LN 4.1 75.5 26 101.5 no 81 110/70 17 100 100 9.1 39 no nil no no 
S20 20 57897 V PRIMI B 159 60 23.73 82 110/70 19 100 130 8.8 39 S LN Ĉ E 5.35 76 25 101 no 84 110/70 19 100 130 8.8 39 no nil no no 
S21 23 18676 V G2P1L1 B 153 56 23.92 84 112/70 17 100 100 8.8 38 S LN 5.26 77 25 102 no 84 110/70 17 100 100 8.8 38 no vomiting no no 
S22 25 10948 V G2P1L1 B 152 53 22.93 82 108/70 16 100 120 8.4 36 I LN 4.2 78 24.5 102.5 no 82 108/70 16 100 120 8.4 36 no nil no no 
PRE DELIVERY POST DELIVERY 
S23 27 39058 V G2A1 UB 155 54 22.47 76 110/70 18 100 100 9 39 S LN Ĉ E 4 73.5 27 100.5 no 78 110/70 18 100 100 9 39 no nil no no 
S24 23 39769 V G2P1L1 B 155 55 22.89 80 128/76 16 100 100 9 40 S LN 4 74 23 97 no 78 128/78 16 100 90 9 40 no nil no no 
S25 24 34567 V G2P1L1 B 156 57 23.42 80 110/80 18 100 120 9 42 S LN 4.35 74.5 26.5 101 no 81 110/80 18 100 120 9 42 no nil no no 
S26 18 45677 V G2P1L1 B 153 56 23.92 80 120/80 19 100 100 8.8 39 I LN 4.37 76.5 25 101.5 no 84 120/80 19 100 100 8.8 39 no nil no no 
S27 26 67373 V G2P1L1 B 155 53 22.06 82 110/70 18 100 100 8.8 40 S LN 4.1 78 24.5 102.5 no 83 110/70 18 100 100 8.6 38 no nil no no 
S28 28 45777 V PRIMI UB 153 57 24.34 84 116/70 19 100 130 8.8 42 I LN Ĉ E 5.3 80 27 107 no 86 116/70 19 100 130 8.8 42 no nil no no 
S29 24 12377 V G2P1L1 B 156 54 22.18 86 114/86 17 100 100 8.8 39 I LN 5.37 74.5 23 97.5 no 86 114/86 19 100 100 8.8 39 no fever no no 
S30 23 59776 V G2P1L1 B 153 55 23.49 88 110/80 18 100 100 8.8 38 I LN 3 73 26 99 no 88 110/80 18 100 110 8.8 38 no nil no no 
S31 29 58776 V G2P1L1 B 154 56 23.61 84 120/70 18 100 120 8.6 37 I LN 4.48 72 27 99 no 85 120/70 18 100 120 8.6 37 no nil no no 
S32 25 56788 IV G2P1L1 B 152 57 24.67 82 110/70 18 99 100 8.6 40 I LN 4.3 70 25 95 no 84 110/70 18 99 100 8.6 40 no nil no no 
S33 25 77676 V G2P1L1 B 155 57 23.72 80 112/70 18 100 100 9 41 I LN 4.2 74 23 97 no 82 114/70 18 100 100 8.8 38 no nil no no 
S34 22 55678 V G2P1L1 UB 153 53 22.64 84 110/80 19 100 125 8.2 40 S LN Ĉ LP 4.2 75 26.5 101.5 no 88 110/80 19 100 125 8.2 40 no nil no no 
S35 20 10453 V G2P1L1 UB 159 58 22.94 80 126/70 18 100 100 8.2 35 S LN 4.25 76.5 25.5 102 no 82 126/70 18 100 100 8.2 35 no nil no no 
S36 27 10457 IV G2P1L1 B 154 54 22.76 82 110/70 18 100 100 9.2 39 S LN 4.39 73.5 24.5 98 no 82 110/70 18 100 100 9 39 no vomiting no no 
S37 30 10987 IV G2P1L1 B 156 57 23.42 84 110/80 17 100 130 9.2 42 S LN 5.3 74.5 26 100.5 no 84 110/80 17 100 130 9.2 42 no nil no no 
S38 21 10432 IV G2A1 B 153 56 23.92 82 116/82 19 100 100 9.4 42 I LN 4.43 74 28 102 no 82 110/88 19 100 100 9.4 41 no nil no no 
S39 26 17432 V G2P1L1 B 155 55 22.89 84 120/80 17 100 100 9 40 I LN 4 75 25 100 no 82 110/70 17 100 100 9 40 no nil no no 
S40 22 20987 IV PRIMI B 152 57 24.67 84 110/70 16 100 100 8.6 39 S LN Ĉ E 4 75 23 98 no 85 110/70 16 100 100 8.6 39 no fever no no 
S41 27 26486 V G2P1L1 B 153 53 22.64 82 122/80 19 100 120 10 39 S LN 4.1 74.5 30 104.5 yes 84 122/80 18 100 120 10 39 no nil yes no 
S42 24 24748 IV G2P1L1 B 153 54 23.06 86 120/70 18 100 100 8.8 38 I LN 4.35 76 24.5 100.5 no 90 124/76 18 100 100 8.8 38 no nil no no 
S43 25 27462 V G2P1L1 B 155 57 23.72 86 110/70 17 100 100 8.8 40 I LN 4.3 77 26.5 103.5 no 90 110/70 17 100 100 8.8 40 no nil no no 
S44 24 28608 IV G2P1L1 B 153 55 23.49 82 114/82 16 100 125 8.6 40 I LN 5 76.5 25.5 102 no 86 114/82 16 100 125 8.6 38 no nil no no 
S45 28 48589 IV G2P1L0 B 154 56 23.61 86 112/70 18 100 100 8.4 38 I LN 4 78 23 101 no 88 112/70 18 100 100 8.4 38 no nil no no 
S46 23 32356 V G2A1 UB 155 55 22.89 84 116/86 18 100 100 8.2 36 S LN Ĉ E 4.15 367 143 510 no 86 110/70 18 100 100 8.2 36 yes nil no yes 
S47 29 47221 V G2P1L1 B 156 57 23.42 80 122/86 19 100 100 9 39  LN 4.25 76.5 26 102.5 no 84 122/86 19 100 100 9 39 no nil no no 
S48 27 16677 V G2P1L0 B 153 54 23.06 82 120/80 17 100 100 9.2 39 I LN 5.12 75 23 98 no 86 120/80 17 100 100 9 39 no nil no no 
S49 22 16674 IV G2PIL1 B 154 56 23.61 82 114/82 17 100 100 9.4 42 I LN 4.5 76.5 24.5 101 no 88 110/80 17 100 110 9.4 40 no nil no no 
S50 19 13683 V G2P1L1 B 154 56 23.61 84 130/80 19 100 130 9 44 S LN 5 75 23 98 no 88 130/80 19 100 130 9 44 no nil no no 
S51 28 35643 V G2P1L1 B 152 56 24.23 84 116/80 17 100 100 9.2 40 S LN 6 75 23 98 no 84 116/80 17 100 100 9.2 40 no nil no no 
S52 24 37843 V G2P1L1 B 155 55 22.89 86 120/70 18 100 130 8.8 38 S LN 4.36 75 24 99 no 88 120/70 18 100 130 8.8 38 no nil no no 
S53 24 38921 V PRIMI UB 158 59 23.63 78 110/70 18 99 100 9.4 42 S LN Ĉ E 4.35 76 25 101 no 80 110/70 18 100 100 9.4 42 no nil no no 
S54 22 39908 V G2P1L1 UB 152 54 23.37 84 120/80 19 99 125 8.6 36 S LN 5.25 78 23 101 no 84 120/80 19 99 125 8.6 34 no nil no no 
S55 27 34564 V G2A1 B 154 53 22.34 80 122/80 18 100 100 10 42 I LN Ĉ E 5.3 74.5 24.5 99 no 82 122/80 17 100 100 10 42 no nil no no 
S56 23 45634 V PRIMI B 156 57 23.42 82 120/70 19 100 110 9.2 40 S LN Ĉ LP 4.18 73.5 23 96.5 no 84 120/70 19 100 110 9.2 40 no nil no no 
S57 35 47687 V G2P1L1 B 152 53 22.93 84 112/70 18 100 100 9.1 38 I LN 4 73 25.5 98.5 no 86 112/70 18 100 100 9 38 no nil no no 
S58 21 47854 V PRIMI B 156 55 22.6 80 112/70 17 100 125 8.5 37 I LN Ĉ E 4.21 76 23 99 no 81 110/70 17 100 125 8.5 37 no nil no no 
S59 29 46968 V PRIMI B 155 54 22.47 80 110/70 18 100 100 9.1 39 S LN 4.1 75.5 26 101.5 no 81 110/70 17 100 100 9.1 39 no nil no no 
S60 20 57897 V PRIMI B 159 60 23.73 82 110/70 19 100 130 8.8 39 S LN Ĉ E 5.35 76 25 101 no 84 110/70 19 100 130 8.8 39 no nil no no 
S61 23 18676 V G2P1L1 B 153 56 23.92 84 112/70 17 100 100 8.8 38 S LN 5.26 77 25 102 no 84 110/70 17 100 100 8.8 38 no vomiting no no 
S62 25 10948 V G2P1L1 B 152 53 22.93 82 108/70 16 100 120 8.4 36 I LN 4.2 78 24.5 102.5 no 82 108/70 16 100 120 8.4 36 no nil no no 
S63 27 39058 V G2A1 UB 155 54 22.47 76 110/70 18 100 100 9 39 S LN Ĉ E 4 73.5 27 100.5 no 78 110/70 18 100 100 9 39 no nil no no 
S64 23 39769 V G2P1L1 B 155 55 22.89 80 128/76 16 100 100 9 40 S LN 4 74 23 97 no 78 128/78 16 100 90 9 40 no nil no no 
S65 24 34567 V G2P1L1 B 156 57 23.42 80 110/80 18 100 120 9 42 S LN 4.35 74.5 26.5 101 no 81 110/80 18 100 120 9 42 no nil no no 
S66 18 45677 V G2P1L1 B 153 56 23.92 80 120/80 19 100 100 8.8 39 I LN 4.37 76.5 25 101.5 no 84 120/80 19 100 100 8.8 39 no nil no no 
S67 26 67373 V G2P1L1 B 155 53 22.06 82 110/70 18 100 100 8.8 40 S LN 4.1 78 24.5 102.5 no 83 110/70 18 100 100 8.6 38 no nil no no 
S68 28 45777 V PRIMI UB 153 57 24.34 84 116/70 19 100 130 8.8 42 I LN Ĉ E 5.3 80 27 107 no 86 116/70 19 100 130 8.8 42 no nil no no 
S69 24 12377 V G2P1L1 B 156 54 22.18 86 114/86 17 100 100 8.8 39 I LN 5.37 74.5 23 97.5 no 86 114/86 19 100 100 8.8 39 no fever no no 
S70 23 59776 V G2P1L1 B 153 55 23.49 88 110/80 18 100 100 8.8 38 I LN 3 73 26 99 no 88 110/80 18 100 110 8.8 38 no nil no no 
S71 19 24390 V PRIMI UB 152 53 22.93 80 112/70 17 99 100 8.4 36 S LN Ĉ E 5 72.5 23 95.5 no 82 110/70 20 99 100 8.4 35 no nil no no 
S72 20 27589 IV G2P1L1 B 152 55 23.80 80 120/70 18 100 120 8.8 38 S LN 5.5 75 24.5 99.5 no 82 120/70 18 100 110 8.8 38 no nil no no 
S73 32 28595 V G2A1 B 154 54 22.76 82 126/76 18 100 100 8.8 38 S LN Ĉ E 4.36 75 25.5 100.5 no 82 120/70 18 100 100 8.8 38 no nil no no 
S74 22 20956 IV G2P1L1 B 155 53 22.06 84 110/70 18 100 125 8.4 36 S LN 5.5 75 24.5 99.5 no 86 108/70 18 100 125 8.2 34 no nil no no 
S75 25 24435 V G2P1L1 B 152 54 23.37 82 122/80 18 100 100 9 38 S LN 6 75 23 98 no 82 120/80 18 100 100 9 38 no nil no no 
S76 24 24467 IV PRIMI UB 153 55 23.49 82 120/70 17 99 100 8.8 38 I LN Ĉ E 4.36 75 25 100 no 84 120/70 17 100 100 8.8 38 no nil no no 
S77 29 26789 V G2A1 B 152 53 22.93 74 120/80 18 100 130 8.6 38 S LN Ĉ LP 5.3 75 24.5 99.5 no 75 120/80 18 100 130 8.6 38 no nil no no 
S78 21 34567 V G2P1L1 B 153 54 23.06 84 110/70 16 100 120 8 36 S LN 5.23 75 26 101 no 86 110/70 16 100 120 8 34 no nil no no 
S79 26 35678 V PRIMI B 156 56 23.01 80 110/80 18 100 130 8.8 40 S LN Ĉ E 4.2 75 26.5 101.5 no 82 110/80 19 100 130 8.8 40 no nil yes no 
S80 23 32414 V G2P1L1 UB 154 53 22.34 82 116/70 19 100 120 9.2 40 I LN 5.36 75 24.5 99.5 no 82 110/70 19 100 120 9 40 no vomiting no no 
S81 27 26486 V G2P1L1 B 153 53 22.64 82 122/80 19 100 120 10 39 S LN 4.1 74.5 30 104.5 yes 84 122/80 18 100 120 10 39 no nil yes no 
S82 24 24748 IV G2P1L1 B 153 54 23.06 86 120/70 18 100 100 8.8 38 I LN 4.35 76 24.5 100.5 no 90 124/76 18 100 100 8.8 38 no nil no no 
S83 25 27462 V G2P1L1 B 155 57 23.72 86 110/70 17 100 100 8.8 40 I LN 4.3 77 26.5 103.5 no 90 110/70 17 100 100 8.8 40 no nil no no 
S84 24 28608 IV G2P1L1 B 153 55 23.49 82 114/82 16 100 125 8.6 40 I LN 5 76.5 25.5 102 no 86 114/82 16 100 125 8.6 38 no nil no no 
S85 28 48589 IV G2P1L0 B 154 56 23.61 86 112/70 18 100 100 8.4 38 I LN 4 78 23 101 no 88 112/70 18 100 100 8.4 38 no nil no no 
S86 23 32356 V G2A1 UB 155 55 22.89 84 116/86 18 100 100 8.2 36 S LN Ĉ E 4.15 367 143 510 no 86 110/70 18 100 100 8.2 36 yes nil no yes 
S87 29 47221 V G2P1L1 B 156 57 23.42 80 122/86 19 100 100 9 39  LN 4.25 76.5 26 102.5 no 84 122/86 19 100 100 9 39 no nil no no 
S88 27 16677 V G2P1L0 B 153 54 23.06 82 120/80 17 100 100 9.2 39 I LN 5.12 75 23 98 no 86 120/80 17 100 100 9 39 no nil no no 
S89 22 16674 IV G2PIL1 B 154 56 23.61 82 114/82 17 100 100 9.4 42 I LN 4.5 76.5 24.5 101 no 88 110/80 17 100 110 9.4 40 no nil no no 
S90 19 13683 V G2P1L1 B 154 56 23.61 84 130/80 19 100 130 9 44 S LN 5 75 23 98 no 88 130/80 19 100 130 9 44 no nil no no 
S91 29 58776 V G2P1L1 B 154 56 23.61 84 120/70 18 100 120 8.6 37 I LN 4.48 72 27 99 no 85 120/70 18 100 120 8.6 37 no nil no no 
S92 25 56788 IV G2P1L1 B 152 57 24.67 82 110/70 18 99 100 8.6 40 I LN 4.3 70 25 95 no 84 110/70 18 99 100 8.6 40 no nil no no 
S93 25 77676 V G2P1L1 B 155 57 23.72 80 112/70 18 100 100 9 41 I LN 4.2 74 23 97 no 82 114/70 18 100 100 8.8 38 no nil no no 
S94 22 55678 V G2P1L1 UB 153 53 22.64 84 110/80 19 100 125 8.2 40 S LN Ĉ LP 4.2 75 26.5 101.5 no 88 110/80 19 100 125 8.2 40 no nil no no 
S95 20 10453 V G2P1L1 UB 159 58 22.94 80 126/70 18 100 100 8.2 35 S LN 4.25 76.5 25.5 102 no 82 126/70 18 100 100 8.2 35 no nil no no 
S96 27 10457 IV G2P1L1 B 154 54 22.76 82 110/70 18 100 100 9.2 39 S LN 4.39 73.5 24.5 98 no 82 110/70 18 100 100 9 39 no vomiting no no 
S97 30 10987 IV G2P1L1 B 156 57 23.42 84 110/80 17 100 130 9.2 42 S LN 5.3 74.5 26 100.5 no 84 110/80 17 100 130 9.2 42 no nil no no 
S98 21 10432 IV G2A1 B 153 56 23.92 82 116/82 19 100 100 9.4 42 I LN 4.43 74 28 102 no 82 110/88 19 100 100 9.4 41 no nil no no 
S99 26 17432 V G2P1L1 B 155 55 22.89 84 120/80 17 100 100 9 40 I LN 4 75 25 100 no 82 110/70 17 100 100 9 40 no nil no no 
S100 22 20987 IV PRIMI B 152 57 24.67 84 110/70 16 100 100 8.6 39 S LN Ĉ E 4 75 23 98 no 85 110/70 16 100 100 8.6 39 no fever no no 
C1 20 10091 IV PRIMI B 152 54 23.37 80 110/70 18 100 100 8.8 42 S LN Ĉ E 5.3 173 36 209 no 86 110/70 18 100 100 8.6 42 no nil no no 
C2 22 10100 V G2PIL1 UB 152 53 22.93 80 122/80 17 100 100 8.8 40 S LN 5.35 174 42 216 no 88 110/70 19 100 100 8.8 40 no nil no no 
C3 24 34354 V G2PIL1 B 154 55 23.19 86 116/72 19 99 100 8.6 38 I LN 4.35 178 37 215 no 90 110/70 19 99 100 8.6 36 no vomiting no no 
C4 25 36778 V G2A1 B 153 54 23.06 84 120/80 18 100 100 8.2 36 S LN Ĉ E 4.55 379 143 522 yes 90 110/70 18 100 100 8.2 36 yes nil no yes 
C5 34 35957 IV G2PIL1 UB 152 55 23.8 80 120/80 18 100 125 9.1 39 I LN 4.3 174.5 36.5 211 no 86 110/70 18 100 125 9 39 no nil no no 
C6 21 32748 V PRIMI B 156 56 23.01 82 130/86 17 100 100 9.1 38 I LN Ĉ E 4.5 173 45 218 no 86 130/80 17 100 100 9.1 38 no nil no no 
C7 29 10114 IV G2PIL1 B 154 53 22.34 80 120/80 19 100 100 9.2 37 I LN 4.25 177 36 213 no 84 110/70 19 99 100 9.2 37 no nil no no 
C8 21 42857 V G2PIL1 B 153 55 23.49 82 118/82 18 100 125 9 36 S LN Ĉ LP 4.35 176.5 42 218.5 no 86 110/80 18 100 130 8.8 36 no nil no no 
C9 23 43857 V PRIMI B 158 60 24.03 84 120/80 17 100 100 9 36 S LN Ĉ E 4.3 173.5 43 216.5 no 88 110/70 19 100 100 9 36 no nil no no 
C10 28 44647 IV G2PIL1 B 153 54 23.06 82 122/78 19 100 100 9 38 S LN 4.4 178 43 221 no 80 120/70 19 100 100 8.6 36 no nil no no 
C11 24 10029 V G2PIL1 B 156 56 23.01 86 120/80 19 100 100 8.8 37 I LN 3.55 173 36.5 209.5 no 90 110/70 19 99 100 8.8 37 no nil no no 
C12 22 10020 V PRIMI B 153 57 24.34 82 126/82 17 100 100 8.8 38 I LN Ĉ E 5.2 176.5 37 213.5 no 86 124/78 17 100 100 8.8 38 no vomiting no no 
C13 23 38575 IV G2PIL1 B 152 53 22.93 80 120/70 16 100 100 8.4 36 S LN 4 175 36 210.5 no 88 110/70 16 100 100 8.4 36 no nil no no 
C14 27 28579 V G2PIL1 B 155 57 23.72 92 126/80 18 100 125 8.6 40 S LN 5.3 178 44 222 no 92 116/70 18 99 125 8.2 34 no nil no no 
C15 19 42957 V PRIMI B 154 54 22.76 84 120/70 18 100 100 8.2 37 I LN 4.2 375 145 520 no 88 118/70 18 100 110 8.2 37 yes fever no yes 
C16 20 11098 IV G2PIL1 B 152 55 23.8 84 120/82 19 100 100 9.4 42 S LN 4.25 376 154 530 yes 88 110/70 19 100 100 9.4 42 yes nil no yes 
C17 26 58938 V G2A1 B 155 53 22.06 86 110/86 18 100 100 10 44 I LN Ĉ E 4.28 173 36.5 209.5 no 90 110/80 18 100 100 10 44 no nil no no 
C18 25 11129 V PRIMI B 154 57 24.03 88 110/80 17 100 130 8.4 40 I LN Ĉ E 4.39 384 156 540 yes 90 110/70 17 99 130 8.2 36 yes nil no yes 
C19 24 28475 IV G2PIL1 B 153 56 24.23 82 120/80 17 100 100 8.6 39 I LN 3.5 178 36 214 no 88 120/80 17 100 100 8.6 39 no nil no no 
C20 26 12332 V PRIMI B 152 54 23.37 78 126/84 19 100 100 8.8 38 I LN Ĉ E 5.3 173 43 216 no 86 120/80 19 100 100 8 35 no nil yes no 
C21 25 39757 V G2PIL1 B 154 53 22.34 80 120/80 19 100 100 9.4 39 I LN 5.34 177 45 222 no 85 120/70 19 100 100 9.4 39 no nil no no 
C22 32 38009 V PRIMI UB 155 57 23.72 80 110/80 19 100 110 8.8 38 I LN Ĉ E 4.35 177 39 215.5 no 86 110/70 19 99 110 8.8 38 no fever no no 
C23 27 12987 IV PRIMI B 152 55 23.8 82 110/70 19 100 100 9.4 37 S LN Ĉ E 4.5 175 42 217 no 88 110/70 18 100 100 9 37 no nil no no 
C24 23 13984 IV PRIMI B 155 56 23.3 82 114/78 18 99 100 9 40 S LN Ĉ E 3.5 174 36 209.5 no 88 110/70 18 99 90 9 38 no nil no no 
C25 27 59003 IV G2A1 B 153 54 23.06 78 110/70 18 100 100 8.2 36 S LN Ĉ E 4.39 176 45 220.5 yes 85 110/70 18 100 100 8.2 32 no nil no no 
C26 24 59039 IV G2P1L0 B 152 57 24.67 84 120/80 18 100 125 8.4 34 I LN Ĉ E 4.58 174 37 210.5 no 90 110/70 18 99 125 8.4 34 no vomiting no no 
C27 20 13900 V G2PIL1 B 154 57 24.03 76 116/78 18 100 100 8.8 40 I LN 5 175 36 210.5 no 86 110/70 18 100 100 8.2 37 no nil no no 
C28 28 58939 V G2PIL1 UB 158 59 23.63 80 120/80 18 100 100 9.4 42 I LN 4.5 177 50 226.5 yes 84 110/80 18 100 100 9.1 40 no nil no no 
C29 23 13990 V G2P1L0 B 153 54 23.06 84 120/78 19 100 100 9.2 41 S LN Ĉ E 4.35 174 43 216.5 no 88 120/70 19 99 100 9.2 38 no nil no no 
C30 18 53928 V G2PIL1 B 152 53 22.93 82 120/80 17 100 135 10 40 S LN 4.25 175 42.5 217.5 no 86 110/70 17 100 135 8.6 37 no nil yes no 
C31 29 14009 IV G2PIL1 B 155 55 22.89 80 110/80 19 100 100 9.2 39 I LN 4.15 177 45 222 no 84 110/70 20 100 100 9.2 39 no nil no no 
C32 21 47119 V PRIMI B 156 54 22.18 82 110/80 18 100 100 9.4 42 I LN Ĉ E 5 174 37 210.5 no 86 110/70 18 99 100 9.1 42 no nil no no 
C33 25 42095 IV G2PIL1 B 153 56 23.92 80 110/80 19 100 125 9.4 40 S LN 4 178 36 214 no 80 110/70 19 100 125 9.1 40 no nil no no 
C34 20 14490 V G2PIL1 B 152 55 23.8 80 122/86 18 100 100 8.6 39 S LN Ĉ LP 3.56 175 44 219 no 84 120/80 18 100 100 8.6 36 no nil no no 
C35 24 49284 V PRIMI B 154 54 22.76 82 120/80 18 100 100 8.8 37 I LN 4.38 177 43 220 yes 88 120/80 18 100 100 8.6 36 no nil no no 
C36 25 14493 IV G2PIL1 B 153 56 23.92 84 120/70 18 100 115 8.4 36 I LN 4.5 178 43 221 yes 88 110/70 18 100 110 8.4 36 no nil no no 
C37 27 34958 V G2PIL1 B 155 56 23.3 86 120/80 18 99 100 8.6 36 S LN 4.25 175 45 219.5 yes 88 120/80 18 99 100 8.6 36 no nil yes no 
C38 21 32948 V G2PIL1 B 153 53 22.64 82 110/80 17 100 100 8.8 38 S LN 4.28 173 36 209 no 86 110/80 17 100 100 8.8 36 no nil no no 
C39 30 14596 V PRIMI B 152 54 23.37 80 120/70 16 100 100 8.2 37 I LN Ĉ E 4.25 177 44 220.5 yes 88 120/70 16 100 100 8.2 36 no nil no no 
C40 21 33048 V G2PIL1 UB 154 57 24.03 82 120/80 19 100 120 8.4 39 I LN 4.1 175 40 215 no 86 120/80 19 99 120 8.4 39 no nil no no 
C41 26 45595 V G2PIL1 B 155 55 22.89 86 110/80 18 100 100 8.6 38 S LN 4.14 177 43 220 yes 90 110/70 19 100 100 8.2 35 yes nil no yes 
C42 23 14593 V G2PIL1 B 153 56 23.92 86 110/86 19 100 100 8.8 40 S LN 5.24 178 45 223 no 90 110/86 19 99 115 8.2 35 no nil no no 
C43 24 33848 V PRIMI B 159 58 22.94 86 110/70 18 100 100 8.4 37 S LN Ĉ E 5.25 175 43 218 no 90 110/70 18 100 100 8.4 36 no nil no no 
C44 23 14900 V G2PIL1 UB 154 57 24.03 84 120/80 17 100 130 8.8 40 S LN 5.5 173 40 213 no 86 120/80 17 100 130 8.8 40 no fever no no 
C45 25 22858 V G2PIL1 B 152 53 22.93 82 110/70 19 100 100 9.1 42 S LN 4.56 177 44 221 yes 88 110/70 19 100 100 9.1 40 no nil no no 
C46 19 15009 V G2PIL1 B 156 56 23.01 86 110/80 18 100 100 9.2 40 S LN 4.35 177 39 215.5 no 90 108/70 18 99 100 8.6 39 no nil no no 
C47 20 50093 V G2PIL1 B 155 53 22.06 86 122/76 19 99 100 9.4 40 S LN 4.23 178 40 218 no 90 122/76 19 99 110 9.4 40 no nil no no 
C48 22 15005 V G2PIL1 B 153 55 23.49 84 110/80 17 99 125 9 41 S LN 4.27 175 44 219 no 88 110/80 17 99 125 9 40 no nil no no 
C49 26 19848 V G2PIL1 UB 153 53 22.64 80 120/82 19 100 100 8.8 39 S LN 4.5 173 37 210 no 84 120/82 18 100 100 8.6 39 no nil no no 
C50 24 16001 V PRIMI UB 152 56 24.23 78 110/80 18 100 135 8.6 38 S LN Ĉ E 5.2 175 45 219.5 no 82 110/70 18 99 130 8.6 37 no nil no no 
C51 27 59003 IV G2A1 B 153 54 23.06 78 110/70 18 100 100 8.2 36 S LN Ĉ E 4.39 176 45 220.5 yes 85 110/70 18 100 100 8.2 32 no nil no no 
C52 24 59039 IV G2P1L0 B 152 57 24.67 84 120/80 18 100 125 8.4 34 I LN Ĉ E 4.58 174 37 210.5 no 90 110/70 18 99 125 8.4 34 no vomiting no no 
C53 20 13900 V G2PIL1 B 154 57 24.03 76 116/78 18 100 100 8.8 40 I LN 5 175 36 210.5 no 86 110/70 18 100 100 8.2 37 no nil no no 
C54 28 58939 V G2PIL1 UB 158 59 23.63 80 120/80 18 100 100 9.4 42 I LN 4.5 177 50 226.5 yes 84 110/80 18 100 100 9.1 40 no nil no no 
C55 23 13990 V G2P1L0 B 153 54 23.06 84 120/78 19 100 100 9.2 41 S LN Ĉ E 4.35 174 43 216.5 no 88 120/70 19 99 100 9.2 38 no nil no no 
C56 18 53928 V G2PIL1 B 152 53 22.93 82 120/80 17 100 135 10 40 S LN 4.25 175 42.5 217.5 no 86 110/70 17 100 135 8.6 37 no nil yes no 
C57 29 14009 IV G2PIL1 B 155 55 22.89 80 110/80 19 100 100 9.2 39 I LN 4.15 177 45 222 no 84 110/70 20 100 100 9.2 39 no nil no no 
C58 21 47119 V PRIMI B 156 54 22.18 82 110/80 18 100 100 9.4 42 I LN Ĉ E 5 174 37 210.5 no 86 110/70 18 99 100 9.1 42 no nil no no 
C59 25 42095 IV G2PIL1 B 153 56 23.92 80 110/80 19 100 125 9.4 40 S LN 4 178 36 214 no 80 110/70 19 100 125 9.1 40 no nil no no 
C60 20 14490 V G2PIL1 B 152 55 23.8 80 122/86 18 100 100 8.6 39 S LN Ĉ LP 3.56 175 44 219 no 84 120/80 18 100 100 8.6 36 no nil no no 
C61 24 49284 V PRIMI B 154 54 22.76 82 120/80 18 100 100 8.8 37 I LN 4.38 177 43 220 yes 88 120/80 18 100 100 8.6 36 no nil no no 
C62 25 14493 IV G2PIL1 B 153 56 23.92 84 120/70 18 100 115 8.4 36 I LN 4.5 178 43 221 yes 88 110/70 18 100 110 8.4 36 no nil no no 
C63 27 34958 V G2PIL1 B 155 56 23.3 86 120/80 18 99 100 8.6 36 S LN 4.25 175 45 219.5 yes 88 120/80 18 99 100 8.6 36 no nil yes no 
C64 21 32948 V G2PIL1 B 153 53 22.64 82 110/80 17 100 100 8.8 38 S LN 4.28 173 36 209 no 86 110/80 17 100 100 8.8 36 no nil no no 
C65 30 14596 V PRIMI B 152 54 23.37 80 120/70 16 100 100 8.2 37 I LN Ĉ E 4.25 177 44 220.5 yes 88 120/70 16 100 100 8.2 36 no nil no no 
C66 21 33048 V G2PIL1 UB 154 57 24.03 82 120/80 19 100 120 8.4 39 I LN 4.1 175 40 215 no 86 120/80 19 99 120 8.4 39 no nil no no 
C67 26 45595 V G2PIL1 B 155 55 22.89 86 110/80 18 100 100 8.6 38 S LN 4.14 177 43 220 yes 90 110/70 19 100 100 8.2 35 yes nil no yes 
C68 23 14593 V G2PIL1 B 153 56 23.92 86 110/86 19 100 100 8.8 40 S LN 5.24 178 45 223 no 90 110/86 19 99 115 8.2 35 no nil no no 
C69 24 33848 V PRIMI B 159 58 22.94 86 110/70 18 100 100 8.4 37 S LN Ĉ E 5.25 175 43 218 no 90 110/70 18 100 100 8.4 36 no nil no no 
C70 23 14900 V G2PIL1 UB 154 57 24.03 84 120/80 17 100 130 8.8 40 S LN 5.5 173 40 213 no 86 120/80 17 100 130 8.8 40 no fever no no 
C71 25 22858 V G2PIL1 B 152 53 22.93 82 110/70 19 100 100 9.1 42 S LN 4.56 177 44 221 yes 88 110/70 19 100 100 9.1 40 no nil no no 
C72 19 15009 V G2PIL1 B 156 56 23.01 86 110/80 18 100 100 9.2 40 S LN 4.35 177 39 215.5 no 90 108/70 18 99 100 8.6 39 no nil no no 
C73 20 50093 V G2PIL1 B 155 53 22.06 86 122/76 19 99 100 9.4 40 S LN 4.23 178 40 218 no 90 122/76 19 99 110 9.4 40 no nil no no 
C74 22 15005 V G2PIL1 B 153 55 23.49 84 110/80 17 99 125 9 41 S LN 4.27 175 44 219 no 88 110/80 17 99 125 9 40 no nil no no 
C75 26 19848 V G2PIL1 UB 153 53 22.64 80 120/82 19 100 100 8.8 39 S LN 4.5 173 37 210 no 84 120/82 18 100 100 8.6 39 no nil no no 
C76 24 16001 V PRIMI UB 152 56 24.23 78 110/80 18 100 135 8.6 38 S LN Ĉ E 5.2 175 45 219.5 no 82 110/70 18 99 130 8.6 37 no nil no no 
C77 20 10091 IV PRIMI B 152 54 23.37 80 110/70 18 100 100 8.8 42 S LN Ĉ E 5.3 173 36 209 no 86 110/70 18 100 100 8.6 42 no nil no no 
C78 22 10100 V G2PIL1 UB 152 53 22.93 80 122/80 17 100 100 8.8 40 S LN 5.35 174 42 216 no 88 110/70 19 100 100 8.8 40 no nil no no 
C79 24 34354 V G2PIL1 B 154 55 23.19 86 116/72 19 99 100 8.6 38 I LN 4.35 178 37 215 no 90 110/70 19 99 100 8.6 36 no vomiting no no 
C80 25 36778 V G2A1 B 153 54 23.06 84 120/80 18 100 100 8.2 36 S LN Ĉ E 4.55 379 143 522 yes 90 110/70 18 100 100 8.2 36 yes nil no yes 
C81 34 35957 IV G2PIL1 UB 152 55 23.8 80 120/80 18 100 125 9.1 39 I LN 4.3 175 36.5 211 no 86 110/70 18 100 125 9 39 no nil no no 
C82 21 32748 V PRIMI B 156 56 23.01 82 130/86 17 100 100 9.1 38 I LN Ĉ E 4.5 173 45 218 no 86 130/80 17 100 100 9.1 38 no nil no no 
C83 29 10114 IV G2PIL1 B 154 53 22.34 80 120/80 19 100 100 9.2 37 I LN 4.25 177 36 213 no 84 110/70 19 99 100 9.2 37 no nil no no 
C84 21 42857 V G2PIL1 B 153 55 23.49 82 118/82 18 100 125 9 36 S LN Ĉ LP 4.35 177 42 218.5 no 86 110/80 18 100 130 8.8 36 no nil no no 
C85 23 43857 V PRIMI B 158 60 24.03 84 120/80 17 100 100 9 36 S LN Ĉ E 4.3 174 43 216.5 no 88 110/70 19 100 100 9 36 no nil no no 
C86 28 44647 IV G2PIL1 B 153 54 23.06 82 122/78 19 100 100 9 38 S LN 4.4 178 43 221 no 80 120/70 19 100 100 8.6 36 no nil no no 
C87 24 10029 V G2PIL1 B 156 56 23.01 86 120/80 19 100 100 8.8 37 I LN 3.55 173 36.5 209.5 no 90 110/70 19 99 100 8.8 37 no nil no no 
C88 22 10020 V PRIMI B 153 57 24.34 82 126/82 17 100 100 8.8 38 I LN Ĉ E 5.2 177 37 213.5 no 86 124/78 17 100 100 8.8 38 no vomiting no no 
C89 23 38575 IV G2PIL1 B 152 53 22.93 80 120/70 16 100 100 8.4 36 S LN 4 175 36 210.5 no 88 110/70 16 100 100 8.4 36 no nil no no 
C90 27 28579 V G2PIL1 B 155 57 23.72 92 126/80 18 100 125 8.6 40 S LN 5.3 178 44 222 no 92 116/70 18 99 125 8.2 34 no nil no no 
C91 19 42957 V PRIMI B 154 54 22.76 84 120/70 18 100 100 8.2 37 I LN 4.2 375 145 520 no 88 118/70 18 100 110 8.2 37 yes fever no yes 
C92 20 11098 IV G2PIL1 B 152 55 23.8 84 120/82 19 100 100 9.4 42 S LN 4.25 376 154 530 yes 88 110/70 19 100 100 9.4 42 yes nil no yes 
C93 26 58938 V G2A1 B 155 53 22.06 86 110/86 18 100 100 10 44 I LN Ĉ E 4.28 173 36.5 209.5 no 90 110/80 18 100 100 10 44 no nil no no 
C94 25 11129 V PRIMI B 154 57 24.03 88 110/80 17 100 130 8.4 40 I LN Ĉ E 4.39 384 156 540 yes 90 110/70 17 99 130 8.2 36 yes nil no yes 
C95 24 28475 IV G2PIL1 B 153 56 24.23 82 120/80 17 100 100 8.6 39 I LN 3.5 178 36 214 no 88 120/80 17 100 100 8.6 39 no nil no no 
C96 26 12332 V PRIMI B 152 54 23.37 78 126/84 19 100 100 8.8 38 I LN Ĉ E 5.3 173 43 216 no 86 120/80 19 100 100 8 35 no nil yes no 
C97 25 39757 V G2PIL1 B 154 53 22.34 80 120/80 19 100 100 9.4 39 I LN 5.34 177 45 222 no 85 120/70 19 100 100 9.4 39 no nil no no 
C98 32 38009 V PRIMI UB 155 57 23.72 80 110/80 19 100 110 8.8 38 I LN Ĉ E 4.35 177 39 215.5 no 86 110/70 19 99 110 8.8 38 no fever no no 
C99 27 12987 IV PRIMI B 152 55 23.8 82 110/70 19 100 100 9.4 37 S LN Ĉ E 4.5 175 42 217 no 88 110/70 18 100 100 9 37 no nil no no 
C100 23 13984 IV PRIMI B 155 56 23.3 82 114/78 18 99 100 9 40 S LN Ĉ E 3.5 174 36 209.5 no 88 110/70 18 99 90 9 38 no nil no no 
 
